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Abstract

Myeloproliferative neoplasms (MPNs) are diseases of hematopoietic stem
cell origin and are characterized by uncontrolled growth of cells of the myeloid
compartment. The Philadelphia chromosome negative classical MPNs, including
polycythemia vera, essential thrombocythemia, and myelofibrosis, are diseases
of dysregulated JAK2 signaling. In fact, the majority of MPN patients have
activating mutations in JAK2 (e.g JAK2-V617F), a tyrosine kinase that
contributes to the growth and survival of myeloid cells. While MPNs were first
described over sixty years ago, a significant need remains to develop therapeutic
strategies for them. Inhibitors of JAK2 are currently being developed, and one
inhibitor, ruxolitinib, was recently approved for certain MPN patients. Ruxolitinib
has made profound impacts on improving splenomegaly and constitutional
symptoms in MPN patients, but it and other JAK2 inhibitors have not significantly
reduced the JAK2 mutant allele burden, and thus such inhibitors have not
induced remission in these patients. The current consensus in the MPN field
supports JAK inhibition for the treatment of patients, but a further understanding
of MPNs and JAK2 signaling, as well as improved JAK2 inhibitors, may be
necessary for treating MPN patients.
The work described in this dissertation has uncovered novel requirements
for JAK2-V617F-driven signaling and transformation. We demonstrate that JAK2V617F co-localizes with lipid rafts, cholesterol-rich microdomains within the
x

plasma membrane that function to serve as platforms for signaling complex
formation. Signaling complex formation is a necessary component for
dysregulated signaling induced by JAK2-V617F. We provide evidence that
cholesterol altering-lipid raft disrupting agents attenuate JAK2-V617F-driven
signaling. We also show that cholesterol-lowering statins are effective at
downregulating JAK2 signaling and inducing apoptosis in JAK2-V617F-driven
cell lines. Importantly, we show that statins, inhibitors of the mevalonate pathway,
inhibit the growth of primary MPN cells, while the same statin doses have no
effect on healthy controls. Impressively, we demonstrate that statins cooperate
with multiple JAK inhibitors, including ruxolitinib, to inhibit cell growth and induce
apoptosis of JAK2-V617F-driven cells.
This report establishes statin-mediated inhibition of the mevalonate
pathway as a potential approach to improve MPN therapeutics. We propose
future studies with statins and JAK2 inhibitors in the treatment of MPNs.

xi

Chapter 1
Introduction

Janus Kinases
Janus kinases, or JAKs, are members of a family of proteins composed of
four members in humans: JAK1, JAK2, JAK3, and Tyk2 [1-2]. JAK proteins act
as important signal transducers of cytokine signaling, and have crucial roles in
normal cellular physiology such as development, proliferation, survival, and
immune regulation through cytokine signaling [3-5]. Knockout murine models
highlight the importance of JAK proteins in normal physiology. JAK1 knockout
mouse models leads to perinatal lethality with severe defects in lymphoid
development [6]. JAK2 knockout mice are embryonic lethal due to defective
erythropoiesis, implicating its role in erythropoietin (EPO), thrombopoietin (TPO),
IL-3, and IL-5 cytokine signaling [7-8]. While JAK3 knockout mice survive, they
experience severe combined immune deficiency (SCID), due to defects in the B
and T cell lineages [9]. Finally, Tyk2 knockout mice survive, but have incomplete
responses to cytokine stimulation [10-11]. JAK1 and JAK2 are ubiquitously
expressed, while expression of JAK3 and Tyk2 is primarily seen in the lymphohematopoietic lineages [12].
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JAK Protein Structure
The JAK family members contain seven homologous domains known as
the Janus homology (JH) domains (Figure 1). At the C-terminus is the JH1
domain, which contains the enzymatic tyrosine kinase region of the protein. The
JH2 domain is also known as the pseudokinase domain and is similar to the
kinase domain in structure. The presence of these two “kinase domains”
provided the inspiration to name these proteins after Janus, the two-faced
Roman God. The pseudokinase domain, however, does not function as the
source of the tyrosine kinase activity of JAKs, but instead functions in an autoregulatory fashion on the kinase domain. For example, deletion of the
pseudokinase domain in JAK2 and 3 enhances kinase activity [13-14]. Up until
recently, it was thought that the pseudokinase domain had no true kinase activity.
Ungureanu et al. showed the pseudokinase domain is capable of
phosphorylating two negative regulatory sites, Ser523 and Tyr570 [15].
Phosphorylation of Ser523 and Tyr570 results in reduced overall JAK2 kinase
activity. Bandaranayake et al. in 2012 demonstrated that the pseudokinase
domain was found to bind Mg-ATP in a non-canonical manner and folds as a
typical eukaryotic protein kinase [16].
The JH3 domain of JAKs comprises the Src-homology-2 (SH2)-like
domain and it is largely not understood how it contributes to JAK activity [17-19],
although it may play a role in homodimeric interactions of JAK2 kinase [20]. JH47 composes the FERM (band 4.1, ezrin, radixin and moesin) domain and is
responsible for interaction with the box 1 and 2 motifs on cytokine receptors.
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Figure 1: Schematic of JAK2 protein domains.

Cytokine Receptors and JAKs
JAKs play a crucial role in cytokine signaling by acting as signal
transducers of cytokine stimulation [1]. Cytokine receptors are transmembrane
receptors that harbor no intrinsic kinase activity and rely on JAKs to transduce
cytokine stimulation signals from the extracellular environment, to ultimately
induce changes in a cell [21]. Cytokine receptors can be divided into two general
classification systems, type I and II cytokine receptors. Type I cytokine
receptors, also named hemopoietin receptors, share a common amino acid motif,
WSXWS located in the extracellular domain adjacent to the transmembrane
domain [22]. Members of the type I receptors family include, but are not limited
to: Interleukin (IL)-2-7, 9, 11, 12, 13, 15, 21, 23, 27, erythropoietin (EPO),
granulocyte macrophage-colony stimulating factor (GM-CSF), granulocyte-colony
stimulating factor (G-CSF), growth hormone, prolactin, oncostatin M (OSM), and
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leukemia inhibitory factor (LIF) receptors [22]. Conversely, type II cytokine
receptors include, but are not limited to: interferon (INF) alpha, beta, gamma, IL10, 20, 22, and 28 receptors. Type II cytokine receptors share sequence
similarity in the extracellular domain in that that contain tandem duplications of
immunoglobulin (Ig)-like domains [22]. Cytokine receptors can bind multiple JAK
family members and because all of these receptors work in dimer or oligomer
complexes, can form a signaling complex with more than one type of JAK [23].
JAK1 and 2 pre-associate with cytokine receptors after final assembly of the
cytokine receptor at the golgi apparatus and prior to translocation to the plasma
membrane [24]. The golgi apparatus is also a site where cytokine receptors can
get post-translational modifications, such as glycosylation [25]. The preassociated receptor/JAK complex and post-translational modifications that occur
at the golgi are thought to promote stability and aid in the transport of these
receptors to the plasma membrane [26].

Canonical JAK/STAT Signaling
Once the receptor/JAK complex reaches the membrane, the receptor and
JAK molecules maintain an inactive confirmation until stimulation by the
receptor’s cognate ligand (cytokine) [27-28]. Cytokine stimulation induces
conformational changes in the cytokine receptor, which bring the JAKs on
adjacent dimer/oligomer receptors in close proximity to transphosphorylate each
other, setting off a cascade of further signaling events. Once JAK molecules are
activated, they phosphorylate tyrosines on the receptor, creating docking sites for
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downstream mediators, such as signal transducer and activator of transcription
(STAT) molecules. STAT molecules bind to the phosphorylated receptor, which
allow for activated JAKs to phosphorylate the STAT molecules. Phosphorylation
of STATs allows for dimerization of STAT molecules, which allow entry of the
transcription factors into the nucleus. Once nuclear, STATs bind to their target
DNA elements and initiate transcription of their target genes [27-28]
Activation of JAK/STAT signaling also leads to activation of
phosphotidylinositol-3’-kinase (PI3K) and AKT and ERK pathways, all of which
contribute to cell proliferation, survival, blocking apoptosis, etc. [29].
Inactive

Active
Cytokine
Cytokine

Cytokine Receptors
(ie. EpoR)

STAT5

STAT5

P
JAK2

JAK2
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P JAK2

JAK2 P

P
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P
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Figure 2: Canonical JAK2/STAT Signaling Pathway. Without
cytokine stimulation pre-associated JAK2 and cytokine receptor
complex localize to the plasma membrane in an inactive conformation.
Upon cytokine stimulation, conformational changes in receptors bring
JAKs in close proximity to transphosphorylate each other. Downstream
mediators, such as STATs get activated and induce expression of
STAT target genes. ERK and Akt pathways activation also occurs with
JAK2 signaling.
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Negative Regulation of Canonical JAK/STAT Signaling
There are a variety of negative regulatory mechanisms to control
JAK/STAT signaling, including suppressors of cytokine signaling (SOCS)
proteins, phosphatases, and protein inhibitors of activated STATs (PIAS) [30-31].
There are eight SOCS family members, SOCS1-8, that function in a classical
negative feedback loop, whereby activation of JAK/STAT signaling leads to the
expression of SOCS proteins. The SOCS family of proteins functions, in large
part by targeting proteins for degradation through formation of an E3 ubiquitin
complex [32]. All SOCS proteins contain an SH2 domain and a SOCS box, the
latter functions to interact with Elongin B/C and Cullin 5, altogether completing an
E3 ubiquitin complex [33-34]. However, there are additional roles associated with
SOCS proteins. SOCS1 and 3 contain kinase inhibitory regions (KIRs) that bind
to the kinase region of JAKs, competing with ATP and blocking kinase activity
[35]. It has also been described that SOCS proteins, using their SH2 domains,
bind to the same sites as downstream mediators, thus competing for binding
sites and downregulating the signaling cascade [33-34]. Phosphatases including
SH2 domain protein tyrosine phosphatase-2 (SHP-2), SHP-1, CD45, protein
tyrosine phosphatase1B (PTP1B), and T cell PTP, among others are also
important in de-activating components of the JAK/STAT pathway by removal of
phosphate groups [36]. Finally, the PIAS proteins include at least four members
in humans, PIAS1-4. PIAS proteins not only inhibit STAT molecules, but other
proteins, namely other transcription factors [37]. PIAS proteins function to target
proteins for degradation by forming complexes with small ubiquitin-related
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modifer1 (SUMO1) and an E2 conjugase. However, PIAS proteins not only target
transcription factors for degradation, but also act to recruit co-regulators that can
block DNA binding sites, and hence transcription [37].

Non-canonical JAK Signaling
JAK signaling has been largely defined by its activity with cytokine
receptors at the plasma membrane, transducing signaling from cytokine
stimulation. Recently, however, JAK2 has been shown to also localize and
function in the nucleus [38]. JAK1 and 2 were shown to phosphorylate tyrosine
41 of histone H3 (H3Y41), which blocks heterochromatin protein 1 alpha (HP 1α)
from binding to this histone region. The complete implications of dual localization
of JAKs in the cytoplasm and nucleus are not yet fully known, however, studies
by Dawson et al. did provide evidence of nuclear JAK2 activity regulating the
expression of the lmo2 gene, an oncogene found in hematopoietic cells. This
implicates JAK2-mediated gene expression alteration by direct histone
modification. JAK2 inhibition by a small molecule inhibitor, led to a decrease in
lmo2 mRNA that correlated with a decrease in phosphorylated H3Y41 and an
increase in HP 1α binding at this locus, providing the first evidence of nuclear
JAK2 contributing to alteration of gene expression [38]. Thus, direct roles of JAKs
outside of cytoplasmic signaling are expanding to include nuclear events such as
histone modification and gene expression.

7

JAK/STAT Pathway Mutations in Humans
Due to the role the JAK/STAT pathway has on promoting proliferation,
survival, differentiation, and immunological responses, it is no surprise that this
signaling cascade is aberrantly regulated in many human diseases, including
cancer, hyper IgE syndrome, and severe combined immune deficiency [39]. This
pathway is fundamental in blood cell production and function, and thus is found
commonly mutated in hematologic malignancies including leukemia, lymphoma,
multiple myeloma, and MPNs [29]. Activating mutations (including point
mutations and chromosomal translocations) in JAK1, 2, and 3 are present in
such malignancies [40-43]. While STAT activation is central to both wild-type and
dysregulated JAK activity, STAT mutations are rare to date [29]. Some patients
with large granular lymphocytic leukemia or lymphoproliferative disorders have
mutated STAT-3 [44], while mutations in STAT-6 have been found in patients
with primary mediastinal B-cell lymphoma [45]. Additional activating mutations
that promote JAK/STAT signaling are found in receptor tyrosine kinases and
cytokine receptors, including: FLT3 (found in AML) [46], KIT (AML) [47], IL-7R
(acute lymphoblastic leukemia, ALL) [48-49], GCSF-R (AML, neutroplilia) [50-51],
and CRLF2 (ALL) [52-53].
Conversely, inactivating JAK/STAT pathway mutations can be found in
patients with myeloid malignancies. Negative regulators including: LNK
(MPN/MDS) [54], SOCS1 (Hodgkin lymphoma [55], MPNs [56], mediastinal
lymphoma [57], PTPN1/2 (T-cell ALL) [58], CD45 (T-cell ALL) [59], and CBL
(MPNs) [60] have been reported.
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Myeloproliferative Neoplasms
MPNs are a group of related hematopoietic stem cell malignancies
characterized by clonal expansion of the myeloid compartment. MPNs were first
described as group of related blood disorders by William Dameshek in 1951 [61].
Specifically, Dameshek grouped chronic myelogenous leukemia (CML),
polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF)
and he believed these disorders had their origin in defective bone marrow, with
the potential to transform to myelodysplastic syndrome (MDS) or acute myeloid
leukemia (AML). It was also suggested by Dameshek that there may be an
underlying genetic commonality to these phenotypically distinct MPNs [61]. With
the discovery of the Philadelphia (Ph) chromosome in CML [62-63], MPNs were
divided into Ph-positive (CML) and Ph-negative (PV, ET, and MF) MPNs.
Subsequently, more hematologic disorders have been classified with Ph-negative
MPNs, including erythroleukemia, but PV, ET, and MF remain classified together
as the classical MPNs [29, 64-65]. For the purposes of this report, the term ‘MPN’
refers to the classical Ph-negative MPNs, PV, ET, and MF.
MPNs are characterized by an overproduction of mature myeloid cells.
MPNs can be deadly on their own due to an increased risk of cardiovascular
events (stroke, heart attack), progression to MF, and bone marrow failure.
Importantly, MPNs can transform into AML at which point myeloid differentiation
is compromised [65]. More details of these diseases will be presented in
forthcoming sections.
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JAK2-V617F
In 2005, five independent groups identified a common somatic mutation in
the JAK2 gene, this mutation leads to a substitution of valine to a phenylalanine
at amino acid residue 617 (JAK2-V617F). The JAK2-V617F mutation is highly
prevalent in the classical MPNs with >95% of PV, 56-60% of ET, and 50% of MF
patients harboring this mutation [66-70]. With this level of prevalence, the JAK2V617F mutation is now incorporated into the diagnoses of these diseases. The
high prevalence of this JAK2 mutation in MPNs highly suggests it plays a
causative role in these diseases.

Ph- Classical MPNs

Disease Characteristics

Frequency of JAK2-V617F

Polycythemia vera (PV)

Expansion of red blood cells

95% VF+

Essential thrombocythemia (ET)

Expansion of platelets

50-60% VF+

Myelofibrosis (MF)

Fibrosis of the bone marrow

50% VF+

Figure 3: Characterization of Ph- classical MPNs. Table describes the
major defining disease characteristics and prevalence of the JAK2-V617F
mutation among Philadelphia chromosome negative (Ph-) classical MPNs,
polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis
(MF).

Importantly, JAK2-V617F has been shown to be necessary and sufficient
to induce an MPN phenotype in mice [71], further suggesting it plays a role in
MPN development. A current hypothesis in the field is that JAK2-V617F gene
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dosage contributes to the disease phenotype. That is, high JAK2-V617F
expression leads to a PV phenotype, while low expression contributes to an ET
phenotype, and an intermediate level contributes to MF. Interestingly, JAK2V617F homozygosity is only found in PV and data from mouse models support
this gene dosage hypothesis [71].
The V617F mutation is located in the pseudokinase domain of JAK2.
Bandaranayake et al. recently resolved the crystal structure for the pseudokinase
domain of both wild-type and JAK2-V617F. This work concluded there is a more
rigid alpha-helix C in the N-lobe in the V617F mutant pseudokinase domain
compared to the wild-type pseudokinase domain [16], providing a possible
explanation for dysregulation of the JAK2-V617F mutant. It is proposed that this
rigid alpha-helix C formation would allow for enhanced transphosphorylation of
JAK molecules. This is presumably because of a decreased ability of the
pseudokinase domain to interact with the activation loop of the kinase domain,
which has been proposed by molecular dynamic simulations [16]. Additionally,
the mutation of amino acid 617 to phenylalanine leads to π stacking interaction
with the nearby F595, and this interaction plays a role in the elevated activation
state of JAK2-V617F [72]. However, even though JAK2-V617F has elevated
kinase activity due to the V617F mutation, it still requires the presence of a
cytokine receptor to signal [73]. Cytokine receptors presumably provide a
scaffolding function for JAK2-V617F proteins to interact and transphosphorylate
each other, as well as to phosphorylate docking sites on the receptor to recruit
signal transducers (Figure 4).
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Other Mutations in MPNs
There is impressive evidence that JAK2-V617F contributes to MPN
formation. This includes the high prevalence of the JAK2-V617F mutation in MPN
patients, the MPN-like disease induced by JAK2-V617F in mouse models, and
the structural studies of the pseudokinase domain explaining a potential mode of
dysregulation of JAK2 kinase activity and subsequent signaling [65]. However,
MPN patients harbor a variety of other activating and inactivating mutations.
While JAK2-V617F is present in 95% of PV patients, it is estimated that the ~5%
of PV patients that are JAK2-V617F-negative have mutations in exon 12 of JAK2
(K539L, etc) [74-75]. These exon 12 mutations have only been identified in PV
and are thought to result in a similar manner of activation as JAK2-V617F, with
loss of the auto-regulatory control on the JAK kinase domain [76]. Molecular
dynamic simulations of JAK2 have suggested this may be caused in part by a
shift in the salt bridge interaction of amino acid residues D620 and E621 with
K539 in wild-type JAK2 to R541 in the JAK2 exon 12 mutant H538Q/K539L [77].
Activating mutations in MPL (myeloproliferative leukemia virus), also
known as gene for the thrombopoietin receptor (TpoR) are found in 4% of ET and
10% of MF patients [78-79]. In particular, substitutions are found at amino acid
residue 515, where tryptophan is substituted for leucine, lysine, or asparagine.
These W515 substitutions allow for MPL to maintain an active conformation to
promote JAK2 activation and signaling in the absence of cytokine stimulation [7879].
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MPN patients also display mutations in negative regulators of JAK/STAT
signaling, including LNK, c-CBL, and SOCS proteins [64]. Cytokine stimulation
(i.e. TPO) promotes the binding of LNK to JAK2, thereby blocking the ability of
JAK2 to phosphorylate downstream mediators, such as STATs. Inactivating
mutations in LNK lead to loss of function and subsequent promotion of
JAK2/STAT signaling [54]. Inactivating mutations have also been identified in
MPNs and myeloid malignancies in the casitas B-cell lymphoma (c-CBL) protein,
an E3 ubiquitin ligase that targets components of the JAK/STAT pathway for
degradation [60].
Additionally, a variety of mutations that modify epigenetic regulation are
found in MPN patients, including mutations in: TET2, IDH1/2, EZH2, ASXL1, and
DNMT3A [64]. Inactivating mutations in TET2 are found in ~10-15% of MPN
patients [80-81]. TET2 catalyzes the hydroxylation of 5-methylcytosine, and
knockdown of TET2 promotes monocyte/macrophage differentiation, implicating
TET2 with a suppressive effect on the differentiation of myeloid cells [82-83]. The
isocitrate dehydrogenase1/2 (IDH1/2) enzymes are also mutated in ~4% of MF
patients [84]. The presence of mutated IDH1/2 suggested predictive value in
determining the patients that transformed to AML [84]. IDH enzymes function in
catalyzing the oxidative decarboxylation of isocitrate to produce α-ketoglutarate,
involved in the citric acid cycle. Rather than producing α-ketoglutarate (αKG),
cancer cells with mutated IDH1/2 produce 2-hydroxyglutarate (2-HG) [85-86].
The switch over of αKG to 2-HG is to the detriment of TET2 because TET2 uses
αKG as a co-activator. Without αKG, TET2 displays impaired functionality,
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ultimately affecting methylation and gene expression [29]. MPN patients also
display inactivating mutations in enhancer of zeste homolog 2 (EZH2) leading to
methylation and subsequent gene expression changes. EZH2 is a histone
methyltransferase that functions in conjunction with the polycomb repressor
complex 2, to alter epigenetic regulation [87]. Additionally, inactivating mutations
in additional sex combs like 1 (ASXL1), which normally binds to histones and
alters chromatin remodeling by a mechanism that is not fully elucidated [88].
Mutations in DNA methyltransferase 3A (DNMT3A) have also been reported in
MPNs. Mutated DNMT3A is thought to contribute to epigenetic alteration and
subsequent gene expression alteration [89]. Multiple modes of dysregulation of
the JAK2/STAT pathway have been described in MPN patients. Figure 4 depicts
mechanisms of hematopoietic transformation in MPNs.

The Life of an MPN Patient
MPN patients can vary in the severity of myeloid cell expansion. While
some patients have elevated levels of myeloid cells that do not require
therapeutic management, others have such a high cellular burden in the
periphery that management is required and life-threatening [65, 90]. The current
standard of care does not change the natural history of MPNs. To manage the
cellular burden, the standard of care includes chemotherapeutic agents such
hydroxyurea, 2-CDA, and busulfan. Phlebotomy is also used to combat the high
cellular burden in the periphery. Additional therapies for MPN patients include
androgens, erythropoietin (EPO), and thalidomide to treat anemia, while
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lenalidamide and interferon (IFN) pegasys may be given to patients suffering
from anemia and splenomegaly [91].
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Figure 4: Mechanisms of JAK2 pathway activation in MPNs. Red
lightning bolts represent mediators that are dysregulated by mutation in
MPNs, these include: activating mutations in cytokine receptors (ie.
MPL), activating JAK2 mutations (JAK2-V617F), inactivating mutations
in the negative regulator LNK, and mutations in nuclear proteins that
alter gene expression (i.e. TET2, IDH1/2, DNMT3A, etc.).
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Splenomegaly, or enlargement of the spleen, occurs in MPN patients due
to extramedullary hematopoiesis, or production of blood components
(hematopoiesis) outside of the bone marrow.Surgery and splenic radiation can
be used to control splenomegaly [91]. The only potential for a cure in MPN
patients is through bone marrow transplant. However, since the average age of
MPN onset is 55, bone marrow transplant is typically not an option because of
the risk associated with transplant [92]. The current goal with MPN treatment is
centered around preventing thrombotic events and hemorrhagic complications,
leading to a lifetime of treatment for many MPN patients [90, 93]. The most
serious risk for MPN patients includes transformation to acute myeloid leukemia
(AML), for AML is incurable and thus leads to a dismal prognosis. MPNs can also
transform into a different MPN. For example, a PV patient can transform to MF
[93]. It is generally thought that cooperating mutations work with mutations that
contribute to dysregulated JAK/STAT signaling. Although poorly understood, it is
hypothesized that the acquisition of particular mutations is what dictates which
MPN may form as well as the transformation of MPNs from one form to another
and to AML [64, 93]. Further understanding these genetic and clinical dynamics
is the goal of ongoing research in the MPN field.

Polycythemia vera
PV patients have a primary defect in the erythrocyte lineage, leading to
expansion of the red blood cells. However, other myeloid cells may also be
dysregulated and expanded in PV. Untreated PV can be life threatening [65, 94-
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95]. There are approximately 22 new PV cases per 100,000 people in the U.S.,
which accounts for ~68,000 PV patients in the U.S [96-97]. There is a minor male
predominance (1.2:1) for PV [98]. The median age of diagnosis for PV is 60
years and is rarely seen in children [98]. The overall mortality of treated PV
patients is 1.6-1.7 times higher than age/sex-matched healthy individuals [99100], with a 15 year survival rate of 65% [99]. A large international study of 1638
patients showed the leading causes of death for PV patients to include:
cardiovascular complications (namely thrombosis, stroke, and hemorrhage), solid
tumors, and leukemic transformation at rates of 45%, 20%, and 13% of deaths,
respectively [101].

Essential Thrombocythemia
The thrombocytic, or platelet, lineage is the primary defective cell lineage
in ET patients, where expansion of this lineage is seen. Similar to PV, ET
patients can also display dysregulation and excess production of other myeloid
lineages [102-104]. The major complications associated with ET include
thrombosis and hemorrhaging because of the high platelet counts. Approximately
2% of ET patients transform to AML, while the overall 15 year survival rate for ET
patients is 73% [99]. It is proposed that ET is the most prevalent Ph- MPN, with
approximately 24 new ET patients per 100,000 people per year in the U.S, which
accounts for ~74,000 ET patients in the U.S. [96-97].
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Myelofibrosis
MF is considered one of the higher risk and heterogeneous Ph- MPNs
[105]. MF patients present with a variety of clinical features including: anemia,
leukocytosis or leucopenia, thrombocytosis or thrombocytopenia, constitutional
symptoms, and splenomegaly [106]. Importantly, fibrosis, or scarring of the bone
marrow is a key feature of MF. Depending on the number of risk factors (age >65
years; hemoglobin <10 g/dL; white blood cell count >25 X 109 /L; peripheral blood
blasts ≥ 1%; and presence of constitutional symptoms), the survival can be
predicted [107]. Patients with a low risk have zero risk factors and are expected
to survive past 11 years. Patients with one risk factor are classified in the
intermediate-1 group and have a median survival of 8 years. Whereas patients
with two risk factors are classified in the intermediate-2 group and have a median
survival of 4 years. High risk patients display ≥ 3 or more risk factors and have a
median survival of 2 years [107]. MF has an incidence rate of 1.46 people in
every 100,000 people in the U.S., accounting for 4,500 MF patients in the U.S.
[97].

JAK Inhibitors
The BCR-ABL inhibitor, imatinib, is highly effective at blocking activity of
the BCR-ABL oncoprotein, resulting in loss of the transforming signaling and thus
is highly effective at killing CML cells [108-110]. The imatinib story is one of
cancers therapy’s best success stories with the five year survival rate being 89%.
Since 95% of CML patients have the BCR-ABL translocation product, imatinib is
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a highly successful treatment for CML patients [108-110]. MPNs parallel the CML
scenario in many regards. A highly prevalent mutation, JAK2-V617F [64], is
found in the majority of MPN patients, just as in the case of BCR-ABL in CML
[108-109]. Secondly, murine models were able to recapitulate both MPNs with
the expression of the single mutation, BCR-ABL recapitulated CML [111], while
JAK2-V617F recapitulated MPNs [71]. Once the discovery of the JAK2-V617F
mutation in MPNs was made, it was hoped the field would take a similar path as
BCR-ABL-targeted imatinib therapy, with JAK inhibitor targeted therapy being
highly effective for MPN patients. Thus, JAK2 inhibitors were quickly developed
and moved into clinical trials.
Many JAK2 inhibitors have been developed including SAR302563,
CYT387, BMS911543 [94], G6 [112], Z3 [113]. These inhibitors are effective at
blocking JAK2-V617F-dependent signaling as well as JAK2-V617F-driven MPN
formation in mice. Several of these inhibitors have moved into clinical trials and
the JAK1/2 inhibitor, ruxolitinib, was approved by the FDA in 2011 for use in MF
patients, just six years after the identification of the JAK2-V617F mutant in
MPNs. Clinically, JAK inhibitors have demonstrated effectiveness in improving
quality of life, reducing constitutional symptoms and splenomegaly, but have not
made significant impacts on reducing the allele burden in MPN patients [94, 114].
Thus, these inhibitors have not provided remission of disease in patients.
However, ruxolitinib use may improve overall survival in high-risk MF patients
and thus there may be some added benefit in addition to relief of symptomology
[94]. JAK inhibitors will likely play an important role in the treatment and
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management of MPNs, but treatment may benefit from combination therapy in
order to reduce allele burden. Even with the similarities between CML and MPNs,
it is becoming clearer that MPNs are a more complex disease consisting of
cooperating mutations in addition to mutations that promote JAK/STAT signaling.
This is unlike BCR-ABL, which is accepted to be the causative agent in CML
[115]. Others and we believe that combination therapy of JAK inhibitors with
additional agents may provide an avenue to reduce allele burden and thus
induce remission in MPN patients [116-117]. Further understanding the
requirements for JAK2-V617F signaling toward cellular transformation may
uncover additional sites for therapeutic intervention for MPNs.

Cholesterol and MPNs
Cholesterol is an essential component of the plasma membrane of
mammalian cells. Due to its hydrophobic properties, cholesterol contributes to
creating a barrier between the cellular contents (organelles, cytoplasm, proteins,
molecules, etc.) and the extracellular environment [118]. Recently, evidence of
cholesterol playing a role in MPN development in mice came to the forefront.
Yvan-Charvet and colleagues found that inhibition of cholesterol efflux, through
knockdown of ATP-binding cassette transporters (ABCA1 and ABCG1) resulted
in an MPN phenotype in mice, implicating a role for cellular cholesterol in MPN
formation. Furthermore, this group showed that high density lipoprotein (HDL), a
molecule that binds cholesterol and promotes its removal from the plasma
membrane, rescued the MPN phenotype in mice [119], again implicating
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cholesterol in development of MPNs. HDL also inhibits hematopoietic stem cell
proliferation, suggesting cholesterol plays a role in regulating blood cell growth
and development. It remains unknown what role cholesterol plays in MPN
development. However, since cholesterol functions in the plasma membrane in
cells it is possible cholesterol-containing lipid rafts are important in this process.

Lipid Rafts
Lipid rafts are defined by the enrichment in cholesterol and sphingolipids,
creating a rigid microdomain within the fluid plasma membrane [120-121]. Lipid
raft biology has improved our understanding of the plasma membrane, where
Singer and Nicholson initially proposed the fluid mosaic model to describe a
plasma membrane. This model describes proteins and molecules moving freely
and randomly in the fluid-like plasma membrane [122]. We now know there is
more order to the membrane, and that order largely comes from lipid rafts. These
tightly packed microdomains arise due to the interaction between the highly
saturated fatty acid side-chains of sphingolipids and the polar head groups of
cholesterol. In comparison to the lipids in the fluid portions of the membrane, lipid
raft sphingolipid acyl chains are generally more saturated, contributing to a
partition of a tightly packed microdomain within the fluid plasma membrane [120121].
Key functions attributed to lipid rafts include providing a platform for
molecular complexes with subsequent effects on signal transduction [121]. This
signal transduction function can be further divided into two categories, inclusion
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and exclusion. Firstly, lipid rafts can allow the inclusion of protein or molecules
into the raft supporting signaling complex formation and molecular interactions.
Examples of the inclusion function include signaling by EpoR [123], the platelet
derived growth factor receptor (PDGF-R), and the insulin receptor [121], each of
which includes the receptor and signaling mediators in lipid rafts. Secondly, lipid
rafts can exclude proteins or molecules from lipid rafts, thereby sequestering
components of signaling complexes. Examples of the exclusion function include
the exclusion of negative regulators from lipid rafts, as in the cases of CD45, a
negative regulator of JAK/STAT signaling that is excluded from lipid rafts after
cytokine stimulation [124] and CD22, a negative regulator of B-cell receptor
(BCR) activation that is excluded from lipid rafts during stimulation of the BCR
[125]. Tied into the alteration of signal transduction function of lipid rafts, is the
potential ability of lipid rafts to alter the functions of proteins due to interactions
with the lipid environment within lipid rafts, whereby depending on the nature of
the protein and lipid raft interactions, the protein may function differently. This is
proposed for some RTKs [124]. Some viruses utilize lipid rafts to gain entry into
cells [126]. Finally lipid trafficking, which aids in the transport of lipids from one
region of the cell to another, is another function attributed to lipid rafts [120-121,
126].
There are two types of lipid rafts, caveolar and non-caveolar lipid rafts. Of
the two types of lipid rafts, caveolae were discovered first, after flask-like
invaginations were detected in the plasma membrane [127-129]. These
membrane invaginations where enriched in cholesterol, sphingolipids, and a
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protein called caveolin-1 (cav-1). Knockout of cav-1 in cell lines shows loss of the
invaginations in the plasma membrane, suggesting a structural function for cav-1
[127]. Similar to caveolar lipid rafts, non-caveolar lipid rafts are enriched in
cholesterol and sphingolipids compared to the fluid phase-plasma membrane.
Also, these two forms of rafts function in the same manner, alteration of signaling
transduction through inclusive or exclusive mechanisms, lipid trafficking, etc.
[120-121]. The key difference between the two types of lipid rafts is the presence
of cav-1, and the subsequent structural dissimilarities in plasma membrane, i.e.
invaginations in the membrane.
The non-caveolar lipid rafts (for the remainder of this report, the term ‘lipid
rafts’ refers to the non-caveolar lipid rafts) were first discovered when small
regions of the plasma membrane remained intact after solublization with nonionic detergents, hence the name detergent resistant membranes, or DRMs [120121, 130]. In fact, it is this property that allows for experimentation and
assessment of lipid rafts. Detergent solublization of the cell leads to lipid rafts
remaining intact, and these non-soluble rafts can subsequently be separated
from whole cell lysate. These small regions were found to be enriched in
cholesterol and sphingolipids, with certain proteins being associated within these
DRMs during a variety of cellular circumstances, such as activation of signal
transduction [121, 130].

Lipid Rafts and JAK/STAT Signaling
Recent work by McGraw et al. demonstrated that wild-type
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EpoR/JAK2/STAT5 signaling is dependent on lipid rafts (Figure 5). EPO
stimulation led to an increase in lipid raft aggregates and subsequent EpoR
localization within the lipid raft. Disruption of lipid rafts resulted in a
downregulation of wild-type EpoR/JAK2/STAT5 signaling [123]. While JAK2V617F-mediated signaling and transformation requires the expression of a
cytokine receptor, such as EpoR, the role lipid rafts may play in dysregulated
signaling by JAK2-V617F has not been investigated. This is a major focus of the
studies of this dissertation.

Mevalonate Pathway
The mevalonate pathway is the key pathway responsible for cholesterol
and isoprenoid biosynthesis (Figure 6). This pathway is present in most
eukaryotes, archaea, and some eubacteria [131]. Overall, this pathway has
important implication in cellular processes such as membrane integrity, protein
prenylation, precursors for hormone production, protein anchoring, and N-linked
glycosylation. The pathway begins with the conversion of acetate to acetyl-CoA,
followed by the combination reaction of acetyl-CoA and acetoacetyl-CoA by 3hydroxy-3methyl-glutaryl-CoA (HMG-CoA) synthase to form HMGCo-A. The rate
limiting enzyme in the pathway, HMG-CoA reductase, catalyzes the conversion
of HMGCo-A to mevalonate. Further downstream from mevalonate and after a
series of reactions, is the production of isopentyl 5-diphosphate (IPP), a major
precursor to downstream isoprenoid products. Subsequently, after radical
coupling reactions with IPP, is the production of farnesylpyrophosphate (FPP).
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FPP can also be converted to geranylpyrophosphate (GPP). The pathway
branches off from the main trunk, where geranylgeranyl diphosphate synthase
catalyzes the reaction that produces geranylgeranylpyrophosphate (GGPP),
which gives rise to geranylgeranylation of proteins such as Ras and Rho.
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Figure 5: JAK2 signaling and lipid rafts. Without cytokine signaling,
JAK2/cytokine receptor (e.g. EpoR) complexes are located outside of
lipid rafts. Upon cytokine stimulation, JAK2/cytokine receptor complex
localize to lipid rafts and promote JAK2 signaling cascade.

FPP can then be converted to dolichol and ubiquinone products. FPP can also
be converted to squalene through a series of reactions, which can be modified to
form cholesterol [131].
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Figure 6: The Mevalonate Pathway. Dashed arrows represent multiple
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The mevalonate pathway is regulated by various mechanisms [131],
including the cholesterol sensing protein, sterol regulatory element-binding
protein-1 (SREBP-1) which promotes expression of HMG-CoA reductase when
cholesterol levels are low. High cholesterol levels promote the exposure of
Lys248 of HMG-CoA reductase, leading to targeting for proteosomal degradation
[132]. Negative feedback loop regulation with the mevalonate pathway end
product, farnesol, has been shown to inhibit HMG-CoA reductase translation.
Additional regulation is also demonstrated through phosphorylation of Ser872 on
HMG-CoA reductase by AMP-activated protein kinase, effectively inhibiting
enzyme activity [133]. Furthermore, cholesterol levels can also be controlled by
cholesterol efflux and influx mechanisms whereby ATP-binding cassette (ABC)
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transporters promote cholesterol leaving the cell, while upregulation of low
density lipoprotein (LDL) receptors promote cholesterol entry into the cell [131].
Needless to say, cholesterol and the mevalonate pathway are carefully regulated
by cells.

Statins
Statins are a class of drugs that inhibit HMG-CoA reductase, the ratelimiting enzyme in cholesterol biosynthesis [134-135]. Statins, since their
approval by the FDA in 1987, have been given to patients to reduce cholesterol.
Statins are effective at treating hypercholesterolemia and preventing a state of
hypercholesterolemia. Statins reduce the morbidity and mortality associated with
cardiovascular disease [134-135]. Currently, there are seven statins on the
market, with both synthetic and naturally occurring statins available [134-136].
These include, among others, simvastatin (Zocor®), atorvastatin (Lipitor®), and
lovastatin (Mevacor®). All statins inhibit HMG-CoA reductase to variable
degrees, and function by binding to the enzyme and thus blocking the ability of
the substrate to enter the active site [137]. Currently, statins are amongst the
best selling drugs in the world and recently became available in generic form in
the United States. A recent estimate shows that over eight million people take
statins and are generally well-tolerated [135, 138].
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Statins and Cancer
Statins are the mainstay treatment to prevent and control cardiovascular
diseases [138]. However, due the large numbers of patients worldwide that take
statins and the large cohorts involved in the hypercholesteremia clinical trials, the
effects statins impose on other aspects of health have been analyzed in a
retrospective fashion. In particular, multiple reports have suggested that statins
reduce the risk of some forms of cancer including: melanoma, breast, colon,
prostate [139-142] and uterine cancer [143]. These and other findings promoted
investigators to more directly test the effects of statins in in vitro and in vivo
cancer models. Indeed, statins were found to be effective at inducing cytotoxic
effects in in vitro cancer models including: melanoma [144], glioma [145],
neuroblastoma [146], and AML cell lines [147]. Mouse models that recapitulated
a variety of cancers including: ErbB2+ breast cancer [148], melanoma [149],
prostate cancer [150], colorectal cancer [151], and leukemia [152] demonstrated
an improvement in survival or tumor regression with statin treatment.

Statins Impact Hallmarks of Cancer
The mode in which statins elicit anti-tumor effects has been under
investigation over the past decade. Multiple groups have shown statins promote
a block in the tumor cell growth in prostate, gastric, AML, pancreatic, colorectal,
melanoma, neuroblastoma, and mesothelioma cancer cell lines [153-154].These
anti-tumor effects were in part due to the inhibition on end products of the
mevalonate pathway, including, inhibition of farnesylpyrophosphate,
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geranylgeranylpyrophosphate, dolichol, and cholesterol production [153].
Additionally, statins were shown to be effective at reducing proliferation induced
by Ras and Rho activation, whose activities are dependent on prenylation.
Furthermore, anti-tumor effects induced by statins are also explained by
stabilizing cell cycle kinase inhibitors, p21 and p27 [155]. In line with blocking
tumor cell growth, statins also have been shown to induce apoptosis through
their ability to upregulate pro-apoptotic Bax and Bim proteins, while
downregulating the anti-apoptotic Bcl-2 protein [153, 156]. Statins have also
demonstrated the ability to induce the activation of caspases 3, 7, 8, and 9 [157159].
Statins block metastatic processes by downregulating endothelial
leukocyte adhesion molecule, E-selectin [160], and matrix metalloproteinase 9
(MMP 9) expression [161], and block tumor cell invasion induced by epithelial
growth factor [162]. Consistent with these data, retrospective analysis of patients
with prostate cancer found that there was a lower incidence of metastatic
progression in patients taking low dose statins for reasons other than cancer
therapeutics, than those who did not take statins [163].
Statins can also impinge on another hallmark of cancer, angiogenesis
[153, 164]. Pro-angiogenic effects have been observed with low dose statin
treatment of rabbits and thus statins under these conditions facilitate tumor
growth. These effects are due in part by activating endothelial nitric oxide
synthase and protein kinase B [165-166]. However, higher doses of statins
resulted in inhibition of angiogenesis [153, 164]. High dose statin treatment can
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decrease vascular endothelial growth factor secretion [167]. These data together
support the concept that statin effects can vary depending on dose.

Statins

Hallmarks of cancer targeted by statins
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Figure 7: Statins target hallmarks of cancer. Statins block the growth
capabilities of cancer by stabilizing p21 and p27, while blocking Ras and
Rho-dependent growth. Statins also can inhibit angiogenesis by decreasing
VEGF expression and blocking capillary tube formation. Apoptosis is also
induced by statin treatment through promoting caspase 3, 7, 8, and 9
activity and inducing pro-apoptotic Bax and Bim. Additionally, statins
promote apoptosis by downregulating Bcl-2 expression, an anti-apoptotic
mediator. Statins are able to downregulate MMP9, while promoting epithelial
growth factor, which contribute to interfering with metastatic processes.
Proteins, and/or their activity, whose names are depicted in red text are
negatively regulated by statins while those depicted in blue text are
positively regulated by statins [153].
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Clinical Trials Using Statins in Cancer Patients
Clinical trials addressing the direct effects of statins on a variety of
cancers in humans have been established. Clinical trials demonstrated that
statins have made positive impacts on tumor/cancer progression in humans with
melanoma, colorectal cancer, breast cancer, uterine cancer, prostate cancer, and
AML [153-154, 168-171]. A clinical trial testing the ability of pravastatin to
improve the survival rate in patients with advanced hepatocellular carcinoma
showed that patients on statins had a survival rate of 18 months, compared to
control group whose median survival was 9 months [172]. Similarly, a clinical trial
with non-metastatic rectal cancer showed that combined treatment with statins
and neoadjuvant chemoradiation, led to 30% of the statin treated patients to have
a complete response, while only 17% in the control group [173]. In addition, prolonged administration of lovastatin in patients with squamous cell carcinoma of
the head and neck resulted in 23% of the patients having stable disease
compared to control group [174]. Concordantly, a small case report of a patient
with acute myeloblastic leukemia showed that lovastatin treatment led to an
apparent stabilization of the number of blast cells [175]. A recent report has
further indicated that statins reduced the mortality associated with cancer after
analyzing the entire Danish population, aged 40 years and up from 1995 to 2007
[176]. However, statins have been ineffective in clinical trials with some cancers.
For example, a clinical trial testing simvastatin in chronic lymphocytic leukemia
patients showed no difference compared to control group [177]. Together these
data suggest that statins may have therapeutic benefit in some, but not all
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cancers. Nonetheless, clinical trials testing statins in cancer patients have shown
some success, supporting further investigation of statin therapy in cancer.

Statins in Combination with Other Agents
Another key aspect to statin treatment in the setting of cancer is the
finding that statins have been found to enhance the effects of other established
chemotherapeutic agents and cytokines [153, 178-179]. For example, lovastatin
and TNFα together enhanced growth inhibition of melanoma and AML cell lines
and increased survival of murine melanoma and AML models [178-179].
Cisplatin, 5-fluorouracil, and doxorubicin have also demonstrated cooperativity
when combined with statins in colon cancer, melanoma, and lung cancer cell
lines [180-183]. Combination treatment of lovastatin and paclitaxel exaggerated
the apoptosis induction compared to single agent treatment alone in AML cell
lines [184]. Interestingly, combination treatment in the case of lovastatin and
doxorubicin, resulted in a reduced risk of doxorubicin-associated cardiotoxicity
[182, 185], suggesting that statins, aside from inducing anti-cancer effect, may
work in combination with other therapies to minimize side effects of treatment.
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Chapter 2
JAK2-V617F-mediated signaling is dependent in lipid rafts and statins
inhibit JAK2-V617F-dependent cell growth

Introduction
Somatic mutations in the gene encoding the JAK2 tyrosine kinase are
prevalent in myeloproliferative neoplasms (MPNs) [66-70, 74], a group of
hematopoietic stem cell diseases characterized in part by expansion of one or
more lineages in the myeloid compartment [186]. Classical MPNs include
polycythemia vera (PV), essential thrombocythemia (ET), and primary
myelofibrosis (PMF). Patients with PV have a defect in the erythroid lineage,
leading to overproduction of red blood cells (RBCs). The main cellular defect in
ET lies within the thrombocytic lineage, resulting in an overproduction of
platelets. In PMF excessive blood cell formation in the bone marrow results in
fibrosis of the bone marrow which can impede proper hematopoiesis [186]. A
recurrent activating mutation in JAK2, JAK2-V617F is found in ~95% of PV
patients and about 50% of ET and PMF patients [187]. Some JAK2-V617Fnegative MPN patients exhibit other mutations that alter JAK2 signaling. These
include exon 12 mutations of JAK2, mutations of cytokine receptors that signal
through JAK2, and mutations of other proteins that regulate JAK2 function.
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Importantly, many of these mutations can initiate an MPN-like syndrome in
mouse models [187]. Collectively, these data suggest that JAK2 dysregulation
contributes to MPN formation.
While JAK2 inhibitors have had significant success in recent clinical trials
due to their ability to reduce constitutional symptoms and thus relieve suffering of
patients, they have not readily reduced the allele burden and thus do not induce
remission in patients [94, 114]. Thus, alternative therapeutic approaches that
enhance neoplastic cell killing are still needed for MPN patients. Further
understanding the regulation of JAK2 signaling in MPN cells may uncover
additional sites of potential therapeutic intervention that may be effective at
treating MPNs.
JAK2 normally functions in signal transduction initiated by cytokine
receptor activation. JAK2 associates with cytokine receptors and becomes
activated following cytokine receptor stimulation by ligand [39]. Cytokine binding
to its receptor causes a conformational change in receptor-associated JAK2
proteins, which then trans-phosphorylate each other leading to their full activation
[73]. Activated JAKs then phosphorylate the cytokine receptor, creating binding
sites for downstream mediators like signal transducer and activator of
transcription (STAT) molecules. STATs are then phosphorylated on tyrosines by
activated JAKs [39]. Phosphorylated STATs function as transcription factors,
promoting expression of genes involved in growth, survival, differentiation, etc. In
the case of JAK2-V617F, the phenylalanine to valine substitution at amino acid
residue 617, allows for dysregulated kinase activity through loss of an
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autoregulatory function of the pseudokinase domain [188]. This mutation
effectively leaves JAK2 primed for activation by circumventing the need for a
conformational change of the kinase induced by cytokine receptor stimulation.
However, even though JAK2-V617F does not require cytokine stimulation to be
activated, a cytokine receptor is still necessary for JAK2-V617F-mediated
signaling and cell transformation [73, 189]. Thus, it is thought that cytokine
receptors provide a scaffolding function for JAK2-V617F-initiated signaling.
Erythropoietin receptor (EpoR) uses JAK2 to transduce signals initiated by
erythropoietin (Epo) to promote RBC production [190]. We have recently shown
that wild-type EpoR/JAK2 signaling requires lipid rafts [123]. Lipid rafts are
microdomains of the plasma membrane that are enriched in cholesterol and
sphingolipids [191]. These microdomains are more rigid than the majority of the
plasma membrane and have been shown to function in membrane trafficking,
cytoskeletal arrangement [120], virus entry [192-193], and cellular signaling
[121]. Protein compartmentalization in membrane rafts facilitates protein
interactions that regulate signal transduction activation, especially for some
receptor-initiated signals at the cell surface [121].
While we have shown that wildtype EpoR/JAK2 signaling requires
membrane rafts for proper signaling [123], the role of cholesterol and membrane
rafts in pathologic signaling by JAK2-V617F in MPNs has never been reported,
and this is what we explored in this study. We show for the first time that JAK2V617F is localized to lipid rafts and JAK2-V617F-dependent signaling requires
membrane cholesterol. By utilizing JAK2-V617F-dependent MPN model cell lines
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as well as primary cells from JAK2-V617F-positive MPN patients, we also show
that JAK2-V617F-mediated transformation is sensitive to statins, inhibitors of the
cholesterol-producing mevalonate pathway. Our data showing the requirement of
cholesterol for JAK2-V617F-mediated signaling and the sensitivity of MPN cells
to statins suggests that statins could potentially be incorporated into a
therapeutic strategy for MPNs.

Results
JAK2-V617F co-localizes with lipid rafts
HEL and SET-2 cells are widely used as MPN model cell lines to study
JAK2-V617F-mediated transformation in MPNs. Each of these patient-derived
cell lines expresses endogenous JAK2-V617F and requires this activated JAK2
for growth [194-195]. We first assessed if JAK2-V617F co-localized with lipid
rafts in cells by utilizing immunofluorescence. We stained HEL cells, which are
homozygous for JAK2-V617F [196], for GM1 ganglioside (red fluorescence), a
lipid raft-associating lipid and JAK2 (green fluorescence) and used single z plane
images from confocal microscopy to visualize localization. Yellow in HEL cell
images represent green and red fluorescence overlap, suggesting JAK2 colocalization with lipid rafts (Figure 8A). The lipid raft disrupting agent methyl-beta
cyclodextrin (MBCD) acts by binding to cholesterol and removing it from the
membrane [197]. When HEL cells were treated with MBCD and stained for JAK2
and lipid rafts, single z plane images from confocal microscopy showed
disruption of red staining, indicative of lipid raft disruption and thus confirming our
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raft staining (Figure 8A). To reduce the possibility of false-positive staining, we
used a second JAK2 antibody and obtained similar results (Figure 8B). To
ensure the antibodies used in staining JAK2 in Figure 1A and 1B were specific
for JAK2, we immunoblotted HEL cell lysates with the same JAK2 antibodies
(Cell Signaling Technology, Inc. used in Figure 1A and Imgenex, Corp. in Figure
8B). Only a single band at the expected molecular weight for JAK2 (~125 kDa)
was detected, demonstrating the JAK2 specificity of the antibodies (Figure 8C).
These same two JAK2 antibodies were also used in a recent study that utilized
immunofluorescence to study JAK2 sub-cellular localization in MPN cells [38].
We next employed a second method to detect the presence of JAK2V617F protein in lipid rafts. Lipid rafts are resistant to Triton X-100 solubilization
and are referred to as detergent resistant membranes (DRMs) because of these
properties. They can be isolated by ultra-centrifugation based on their differential
buoyant density compared to other membranes and cellular constituents [121].
We utilized an iodixanol gradient to isolate DRMs from Triton X-100 solubilized
SET-2 whole cell lysate. After centrifugation, fractions were removed from the top
of the gradient, resulting in lower density fractions being present in the lower
numbered fractions. Equal volumes of each fraction were analyzed by dot blot
analysis to identify the fractions containing the resident raft lipid marker GM1
ganglioside (Figure 9A). GM1 was detected predominantly in fraction 2, as well
as in fractions 3, 5, and 6. Separation of GM1 between fractions 3 (lower buoyant
density) and 5 (higher buoyant density) suggests that DRMs separated from the
whole cell lysate (fractions 5 and 6), and identifies the lower buoyant
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Figure 8: Mutant JAK2 co-localizes with lipid rafts in JAK2-V617Fpositive cells. (A) HEL cells, untreated (left) or treated with MBCD (10 mM,
30 min, right), were stained with antibodies that recognize JAK2 (Cell
Signaling Technology, CS) (green) and lipid rafts were detected by CTB,
which binds to lipid raft lipid, GM1 ganglioside (red). Co-localization is
demonstrated by merging green and red images, creating yellow. 4’ 6diamidino-2-phenylindole (DAPI) was used to stain the nucleus (blue). Cells
were analyzed by confocal microscopy and single z plane images are
shown. (B) The experiment in (A) was repeated using a second JAK2
antibody (Imgenex, IMG). (C) Immunoblot analyses showing total JAK2
expression in HEL cells using two different antibodies, CS (left blot) versus
IMG (right) blot, used in (A) and (B), respectively, are shown. Molecular
weights are indicated in kDa. Immunoblots demonstrate specificity to JAK2
(c. 125 kDa).
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density fractions as raft-containing fractions (fractions 2 and 3) (Figure 9A). We
then analyzed each fraction by immunoblotting for JAK2. Although the majority
of JAK2 was present in the lower/cell lysate fraction (fraction 6), JAK2 was
detectable in the raft fraction (fraction 2) in the untreated SET-2 cells (Figure 9B).
A resident raft protein, Flotillin-1 was primarily detected in fraction 2, supporting
our raft fraction designation. However, when SET-2 cells were treated with
MBCD, JAK2 was no longer found in the lower buoyant density fraction 2, but
solely in the higher buoyant density non-raft fractions (higher numbered
fractions), suggesting that raft disruption by MBCD altered JAK2 protein
localization (Figure 9C). MBCD treatment also shifted the raft marker Flotillin-1
from raft fractions to higher density buoyant fractions (higher fraction numbers),
demonstrating effective disruption of lipid rafts (Figure 2C). Based on our
immunofluorescence and DRM isolation data, we conclude that JAK2-V617F can
be detected in lipid rafts, and the lipid raft-disrupting agent, MBCD, can abrogate
this sub-cellular localization.

Lipid raft disrupting agents downregulate JAK2/STAT5 activation in JAK2-V617Fdependent cell lines
Because JAK2-V617F localization in lipid rafts was abrogated by the raftdisrupting agent, MBCD, we next investigated the effect lipid raft disrupting
agents had on signaling induced by JAK2-V617F. To test this we treated the
JAK2-V617F-dependent patient-derived cell lines HEL, SET-2, and Uke1 with
lipid raft disrupting agents, which function by affecting membrane cholesterol.
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Figure 9: JAK2 is present in fractions containing detergent
resistant membranes. (A) SET-2 cell lysates were analyzed by
density buoyant gradient fractionation. Fractions were removed
from the top of the gradient and thus lower fraction numbers
correspond to lower buoyant density fractions. Each fraction
was analyzed by dot blot for GM1 ganglioside, a resident raft
lipid, using CTB as a probe. Separation of GM1into lower and
higher buoyant density fractions suggests separation of DRMs.
Highest detection of GM1 is present in fraction 2, thus
designating fraction 2 as the raft fraction. (B) Immunoblot
analyses of gradient fractions of untreated cells to detect JAK2
or the resident lipid raft marker, Flotillin-1. (C) Immunoblot
analyses for JAK2 and Flotillin-1 as in (B), but utilizing MBCDtreated SET-2 cells. MBCD re-distributed JAK2 and Flotillin-1 to
the higher density non-raft fractions. Molecular weights are
indicated in kDa.

These cell lines express JAK2-V617F and JAK2 signaling, including STAT5
activation, is dependent on JAK2-V617F [194]. MBCD treatment of HEL cells
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decreased P-JAK2 as shown by immunoblotting for P-JAK2 in total cell lysates
(Figure 10A) and in JAK2 immunoprecipitations (Figure 10A, right panel).
Activation/phosphorylation of STAT5 was effectively eliminated by MBCD
treatment. Additionally, MBCD treatment resulted in a marginal decrease in PAkt, another downstream effector of JAK2-V617F activity, in HEL cells (Figure
10A). Similar results were seen in SET-2 cells where MBCD treatment
significantly decreased P-JAK2, P-STAT5, and P-Akt (Figure 10A). Likewise,
MBCD treatment decreased P-STAT5 and P-AKT levels in Uke1 cells (Figure
10A). To test the effect of lipid raft disruption in a non-JAK2-V617F transformed
myeloid cell line, we treated K562 cells, which display constitutive JAK2/STAT5
signaling due to the activated BCR-ABL tyrosine kinase, with MBCD. MBCD
treatment did not significantly affect activation of JAK2 or STAT5 in K562 cells
(Figure 10B),
Filipin complex is a lipid raft disrupting agent that functions through a
different mechanism than MBCD. While MBCD removes cholesterol from the
membrane, filipin complex binds to cholesterol in the membrane thereby
interfering with proper lipid raft integrity [198]. Filipin complex is a weaker lipid
raft disruptor than MBCD [199-200]. Filipin complex treatment of HEL cells also
led to a decrease in JAK2/STAT5 activation, with a modest effect on P-JAK2 but
a significant reduction of P-STAT5 (Figure 10C).
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Figure 10: Lipid raft disrupting agents downregulate signaling in
JAK2-V617F-dependent MPN model cell lines. (A) The JAK2-V617Fdependent cell lines HEL, SET-2, and Uke1 were left untreated (-) or
treated with MBCD (10 mM) for 30 minutes (+). Lysates were analyzed by
immunoblotting with antibodies that recognize phosphorylated/activated (P) JAK2, STAT5, and Akt, as well as total JAK2, STAT5, and Akt, as
indicated. Arrow indicates mobility of JAk2 (125 kDa) in SET-2 cells. (B)
K562 cells, a BCR-ABL-positive CML cell line that has wild-type JAK2, but
constitutive JAK2/STAT5 activation, were left untreated (-) or were treated
with MBCD (+) as in (A) and analyzed by immunoblotting with antibodies
that recognize P-JAK2, JAK2, P-STAT5, and STAT5, as indicated. (C) HEL
cells were left untreated (-) or were treated filipin complex (1 µg/mL) for 15
minutes (+). Lysates were analyzed by immunoblotting with antibodies that
recognize P-JAK2, JAK2, P-STAT5, and STAT5, as indicated.

Statins inhibit growth and viability of JAK2-V617F-dependent cells
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HEL, SET-2, and Uke1 cells require JAK2-V617F signaling for growth
[194-195] and our data indicates lipid raft disruption has a negative effect on
JAK2-V617F-dependent signaling (Figure 10). We next wanted to disrupt
JAK2-V617F localization in lipid rafts in a longer term of study in order to analyze
effects on growth and survival of these JAK2-V617F-dependent cells.Statins
inhibit the rate-limiting enzyme, HMG-CoA reductase, in the mevalonate pathway
which leads to cholesterol biosynthesis [201] and can also be used to alter
cholesterol-rich lipid rafts [202]. In addition, statins have been shown to alter the
localization of cytokine receptors (e.g. EpoR) to the plasma membrane, which
could also affect JAK2-dependent signaling in lipid rafts [203]. Simvastatin
treatment of HEL cells, as well as SET-2 cells, led to a dose-dependent reduction
in total viable cell numbers over time (Figure 11A). Similar results were seen with
lovastatin and atorvastatin (data not shown). Simvastatin treatment reduced the
viability of HEL cells, while the viability of K562 cells was not significantly affected
(Figure 11B). Since we utilized statins to target cholesterol, we wanted to confirm
cholesterol levels were indeed affected. We determined that the low dose of
simvastatin we utilized in this study did indeed decrease cholesterol levels in
HEL cells (Figure 11C), with 5 µM simvastatin reducing cellular cholesterol by
~34% after four days of treatment. Similarly, cholesterol reduction was observed
with lovastatin and atorvastatin treatment (not shown). Finally, statin treatment
inhibited the localization of JAK2-V617F to lipid rafts as determined by
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Figure 11: Simvastatin reduces JAK2-V617F-dependent cell viability and
growth. (A) HEL (left graph) or SET-2 (right graph) cells were treated with 0
(0.1% dimethyl sulfoxide, DMSO) to 10 µM simvastatin (Sim). Trypan blue
exclusion was used to enumerate total viable cells over time. (B) Percent
viability of HEL (left graph) and K562 (right graph) cells was determined by
trypan blue exclusion over time following either DMSO or 5 µM simvastatin
(Sim) treatment. Data shown is representative of three independent
experiments. (C) Cholesterol was measured in HEL cells after 4 d of 0
(DMSO), 1 µM, or 5 µM simvastatin treatment. Error bars indicate standard
deviation and p value was determined by T-test (GraphPad Software, Inc.)
This experiment is representative of three independent experiments. (D) Colocalization of JAK2-V617F and lipid rafts in HEL and SET-2 cells was
performed as in Figure 1A and the Pearson’s correlation analysis for colocalization was determined using Definiens Developer software. Data
represents the average (with standard deviation) correlation coefficient for
four to five images for each condition for each cell line.
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immunofluorescence (Figure 11D), however it did not disrupt lipid raft formation
(data not shown).

Simvastatin induces apoptosis and downregulates JAK2/STAT5 activation in
JAK2-V617F-dependent cell lines
Since we observed a decrease in cell viability with statin treatment, we
next assessed if statins could induce apoptosis of JAK2-V617F-dependent cell
lines. Simvastatin treatment (5 µM) induced apoptosis of HEL cells as measured
by annexin V staining (Figure 12A). PARP cleavage after simvastatin treatment
of HEL cells for 24 and 48 hours also demonstrated simvastatin induced
apoptosis in a dose and time-dependent manner, even at the very low dose of 1
µM (Figure 12B). Induction of PARP cleavage was also seen in SET-2 cells
treated with simvastatin (Figure 12B). Simvastatin treatment of HEL cells
reduced the activated/phosphorylated levels of JAK2 and to a less significant
extent STAT5 (Figure 12C). Similar results were seen in SET-2 cells (Figure
12C). However, JAK2/STAT5 activation in K562 cells was less sensitive to
simvastatin treatment than in JAK2-V617F-dependent cells (Figure 12C).

Simvastatin inhibits Primary MPN Cell Growth
Hematopoietic progenitor cells from MPN patients form erythroid colonies
in methylcellulose medium lacking erythropoietin (Epo) [204]. To test the effects
of statin treatment on primary MPN cells we performed colony formation assay
using mononuclear cells (MNCs) from peripheral blood of two JAK2-V617F-
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Figure 12: Simvastatin induces apoptosis and downregulates
JAK2/STAT5 activation in JAK2-V617F-dependent cells. (A) HEL cells
were treated 0 (DMSO), 1 µM, and 5 µM simvastatin for 24 and 48 hours and
stained with Annexin V and analyzed by flow cytometry to detect Annexin Vpositive cells. Error bars indicate standard deviation of triplicate samples. This
experiment was performed four times with similar results. (B) Immunoblot
analysis to detect PARP cleavage after 0 (DMSO), 1 µM, and 5 µM
simvastatin treatment of HEL cells (top blot) and SET-2 cells (bottom blot) for
24 and 48 hours. (C) HEL, SET-2, and K562 cells were treated with 5 µM
simvastatin for 4 d and cellular lysates were analyzed by immunoblotting for
P-JAK2, JAK2, P-STAT5, STAT5, and Hsp90 (as additional loading control),
as indicated.
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positive MPN patients. Thus, JAK2-V617F-positive erythroid progenitors will
proliferate and differentiate to form erythroid colonies in the absence of Epo.
Simvastatin reduced Epo-independent erthyroid colony formation of cells from
three independent MPN patients tested (Figure 13A). These patients included a
JAK2-V617F-positive PV patient (MPN 1), a JAK2-V617F-positive MF patient
(MPN 2), and a JAK2-V617F-positive post-PV/MF patient (MPN 3). Inhibition of
colony formation was seen with 5 µM simvastatin. We utilized simvastatin at 2.5
µM in the experiment with MPN 3 and this lower dose inhibited colony formation
to a similar extent (~75%). Similar experiments performed with cells from normal
healthy controls (n=4) suggested erythroid colony formation from normal
progenitor cells is unaffected by statin treatment at the same dose that shows
efficacy at reducing colony formation of cells from MPN patients (Figure 13B).

Discussion
JAK inhibitor therapy was recently approved for the treatment of MF
patients. JAK inhibitors have proven to be effective at improving constitutional
symptoms and reducing spleen size in MPN patients. However, they do not
appreciably decrease disease allele burden and thus do not induce remission in
patients [94, 205]. JAK inhibitors can block the aberrant JAK2 and JAK1
signaling induced by the cytokine storm associated with MPNs, and this may be
the basis for improvement in MPN patients’ constitutional symptoms [94, 205].
With the inability of JAK inhibitors to decrease the allele burden in MPN patients,
exploration of alternative therapeutic approaches for MPN patients continues. We
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Figure 13: Simvastatin reduces erythroid colony formation of
primary MPN cells. (A) Colony formation assay performed using
mononuclear cells (MNCs) isolated from peripheral blood of MPN
patients (n = 3). MNCs were plated in cytokine containing
methylcellulose medium without Epo and Epo-independent erythroid
colonies [as erythroid burst-forming units (BFU-Es)] were enumerated
after 12 d of incubation. The experiment performed with either 0
(DMSO), 2.5 µM, or 5 µM simvastatin (Sim), as indicated. Data is
presented as number of BFU-Es per 105 cells plated. MPN patients 1, 2,
and 3 are a JAK2-V617F-positive PV patient, a JAK2-V617F-positive MF
patient, and a JAK2-V617F-positive post-PV/MF patient, respectively.
(B) The same experiment was performed with cells from healthy controls
(n = 4) and with erythropoietin in the medium. All error bars represent
the standard deviation of replicate plates.
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initiated our studies to further our understanding of the requirements for JAK2V617F-mediated signal transduction in an effort to uncover novel avenues for
therapeutic intervention for MPNs. We recently demonstrated that EpoR/JAK2
signaling requires lipid raft formation [123] and thus wanted to determine the
potential role of lipid rafts in deregulated JAK2 signaling in MPNs. While previous
studies support the notion that JAK2 functions in lipid rafts [123, 206], our studies
are the first to demonstrate that the MPN driver JAK2-V617F co-localizes with
lipid rafts (Figures 1 and 2). Localization of this tyrosine kinase to lipid rafts is not
seen in all cells, largely because not all cells exhibit raft staining (Figure 1). This
may be due to the dynamic nature of lipid rafts, which is influenced by factors
such as variability in raft size and half-life [207-211]. In addition, only a minor
fraction of JAK2 was associated with DRMs. This is not surprising for multiple
reasons. First, rafts are dynamic in nature and all cells did not display raft
staining. Second, JAK2 is a cytoplasmic protein and more recently has been
found in the nucleus of cells, including MPN cells [38, 212]. Third, our hypothesis
is that JAK2-V617F is associated with a transmembrane receptor, such as a
cytokine receptor (e.g. EpoR). Therefore, JAK2-V617F is not physically present
in rafts per se, but rather associated with a protein in rafts. DRM isolation
experiments utilize an overnight ultracentrifigation spin and it is likely that some
JAK2 protein would not maintain its interaction with raft-associated proteins
during this protocol and thus fractionate with the remainder of the JAK2, which is
non-raft associated.
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Using agents that disrupt cholesterol in the plasma membrane, we found
that JAK2 and STAT5 activation in JAK2-V617F-dependent cells were dependent
on cholesterol in the plasma membrane, while JAK2 and STAT5 activation in
K562 cells, which express wildtype JAK2, were not (Figure 3). JAK2-V617F
requires cytokine receptors for activation [73, 189] while wildtype JAK2 activation
in K562 cells is likely induced by the BCR-ABL tyrosine kinase [213-214]. We
believe that JAK2 activation by mechanisms that involve a cell surface receptor
may be more sensitive to lipid raft disruption than activation of JAK2 by nonreceptor mechanisms, such as BCR-ABL. The BCR-ABL induced constitutive
JAK/STAT signaling may not rely on lipid rafts because the cytoplasmic BCRABL tyrosine kinase may activate or signal to these molecules directly [213-214].
Lipid rafts may play an integral role in the receptor scaffolding function for JAK2V617F activation by coordinating the proper molecular complexes at the cell
surface [73, 121, 189].
MPN model cell lines are also more sensitive to statin treatment than
BCR-ABL positive K562 cells. We find MPN cells are sensitive to single digit
micromolar statins, which is similar to certain AML cell lines, but significantly less
than cells from a variety of solid tumors [215]. This may, in part, be due to the
inherent driving oncogenic lesions in these cells, compared to other cancers.
Statin treatment also inhibited the growth of primary MPN cells. Importantly, the
growth of primary MPN cells is more sensitive to statins than cells from healthy
controls (Figure 6). This is in agreement with other studies looking at the effect of
statins on normal and neoplastic hematopoietic cell growth, where normal
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hematopoietic cells are not sensitive to statins until high doses are achieved
[215-217]. This suggests statins may be considered as a potential therapeutic
agent for MPNs, although the effect of statins on JAK2-V617F-negative MPNs
needs to be determined.
Although a requirement for lipid rafts in JAK2 signaling could provide a
mechanistic rationale for the use of statins to inhibit MPN cells, cholesterol is not
the only end product of the mevalonate pathway [169]. While we have not
obtained evidence that statins inhibit lipid raft formation in our cell systems, we
show that statins do appear to inhibit the localization of JAK2-V617F to lipid rafts
(Figure 4D), which in effect also targets the requirement of rafts for signaling.
Importantly, statins also inhibit protein prenylation by inhibiting the production of
farnesyl pyrophosphate and geranygeranyl pyrophosphate, two other end
products of the mevalonate pathway downstream of HMG-CoA reductase.
Interestingly, it has been shown that EpoR cell surface expression requires
protein geranylgeranylation [203]. It is possible that the effects of statins in MPN
cells may be mediated through protein prenylation, perhaps through inhibition of
a requisite cytokine receptor for JAK2-V617F-mediated signaling. In our efforts to
ascertain further details regarding the mechanism of statin affects on MPN cells,
we have determined that adding back geranylgeranyl pyrophosphate to cells can
reduce the statin-induced loss of viability of cells, but does not significantly
restore proliferation of cells (not shown). Thus, while the mechanistic details by
which statins inhibit MPN cell growth are likely complex and remain to be
elucidated, our data suggest that statins may be a candidate to be used as a

51

potential therapeutic strategy to target MPN cells. While these details will be the
focus of future studies, it is important to note that statins induce MPN cell
apoptosis (Figure 5A and B). This is significant since JAK2 inhibitors fail to
decrease allele burden in patients, additional therapeutic approaches to
complement JAK2 inhibitors are needed, especially ones that can contribute to
an apoptotic response in MPN cells.
While our work is the first to directly investigate the role of lipid rafts and
cholesterol in MPN cells, there is additional evidence that suggests cellular
cholesterol levels could play a role in MPN cell biology. Mice deficient in
cholesterol efflux transporters ABCA1 and ABCG1 display an MPN-like
phenotype [119]. This suggests that an increase in cellular cholesterol in
hematopoietic cells can lead to an MPN-like phenotype. In fact, Yvan-Charvet et
al. [119] demonstrated that hematopoietic stem and progenitor cells from these
mice displayed aberrant proliferation, and that removal of cholesterol from these
cells restored a normal proliferative phenotype. These studies clearly indicate
that cellular cholesterol can regulate growth control pathways of hematopoietic
stem and progenitor cells, and that increasing cholesterol levels can lead to
aberrant myeloproliferation. Thus, cellular cholesterol may play an important role
in the development of human MPNs. Our work showing that alteration of
membrane cholesterol with lipid raft disrupting agents inhibits JAK2-V617F
signaling, together with Yvan-Charvet et al [119], suggests that altering
cholesterol in hematopoietic stem and progenitor cells may affect cell signaling
that leads to JAK2-V617F-driven myelopoiesis. Thus, altering cellular cholesterol
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or inhibiting localization of JAK2-V617F to lipid rafts, perhaps through the use of
statins, may be an effective approach to target the aberrant myelopoiesis
associated with MPNs.
The use of statins to treat MPN patients has been previously rationally
suggested [218-219]. This hypothesis is based on the antithrombotic,
antiproliferative, proapoptotic, and antiangiogenic effects of statins and the role
thrombohaemorrhagic complications play in MPNs. The use of statins in the
treatment of MPNs has been discussed in the context of the potential role of
chronic inflammation in the development of MPNs. The anti-inflammatory effects
of statins may be advantageous to MPN patients as chronic inflammation may be
a driving force toward clonal evolution as well as a deadly myelofibrotic state
[218-219]. For example, TNFα may contribute to clonal expansion of MPN cells
[220] and simvastatin lowers TNFα expression in myeloid cells in patients [221].
Also, MPN patients have an increased risk of developing both hematologic and
non-hematologic secondary cancers and this may be due to the elevated
inflammation associated with MPNs [91, 222]. Thus, in addition to potential direct
effects of statins on MPN cells, statins may also contribute to the amelioration of
disease through their anti-inflammatory effects.
In summary, we find that JAK2-V617F is associated with lipid rafts and
that signaling by this constitutively activated kinase is dependent on proper lipid
raft formation. Statins reduce JAK2 localization to lipid rafts, induce apoptosis of
MPN cells, and inhibit colony formation of primary cells from MPN patients. Since
JAK inhibitors have not had success at reducing allele burden in MPN patients,
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additional therapeutic approaches are needed in order to induce remission in
these patients. Our work suggests that statins might be an effective component
of a therapeutic strategy for MPN patients. Additional studies are needed to
investigate the potential efficacy of statins, alone and in combination with JAK
inhibitors, as a potential therapeutic option for MPNs.

Materials and Methods
Immunofluorescence studies
HEL cells were treated with 10 mM MBCD (Sigma-Aldrich) for 30 minutes
at 37ºC and 5% CO2. Cells (2 X 106) were washed with chilled RPMI
supplemented with 10% FBS, followed by a 10 minute incubation with 1 ug/mL
cholera toxin B (CTB)-conjugate (Vybrant Lipid Raft Labeling Kit, Life
Technologies) in chilled RPMI/10% FBS for 10 minutes at 4ºC. Cells were
washed three times with chilled PBS. For experiments in which Imgenex JAK2
antibody was utilized, anti-CTB antibody (Vybrant Alexa Fluor 594 Lipid Raft
Labeling kit, component B) was then performed for 10 minutes at 4ºC. Cells (2.55 X 104) were cytospun onto glass microscopes slides. Cells were then fixed
using Cytofix Fixation Buffer (BD Biosciences) for 10 minutes at 37º C and
washed with RT PBS. Cells were then permeabilized for 5 minutes using 2 drops
of 0.5% Triton X-100 in PBS. Slides were washed using RT PBS and
subsequently blocked with 2% BSA in PBS for 30 minutes at RT and washed
with RT PBS. Primary antibody incubation followed, using a 1:200 dilution (in 2%
BSA/PBS) for JAK2 (D2E12, Cell Signaling) or (IMG-3007, Imgenex, Corp.)
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overnight (o/n) at 4º C. Slides were washed with RT PBS. Secondary antibody for
JAK2 ensued using Alexa Fluor 488 goat-anti-rabbit (Invitrogen, #411008) at
1:500 dilution (in 2% BSA/PBS) for 1 hour at RT for the JAK2 (Cell Signaling)
primary, or DyLight 488 Conjugate donkey-anti goat secondary antibody (705486147, Jackson Immunoresearch Laboratories) at a 1:500 dilution for JAK2
(Imgenex, Corp.) primary. Slides were washed with RT PBS. Mounting media
(ProLong Gold antifade reagent with DAPI, Invitrogen) was added to each slide
and covered with a cover slip. Confocal microscopy with a Leica TCS SP5 AOBS
laser scanning confocal microscope (Leica Microsystems, Germany) was used to
image cells as previously described [123]. Definiens Developer version 1.5
(Definiens AG, Munich, Germany) was used to perform Pearson’s Correlation
analysis for colocalization between lipid raft and JAK2 staining on an average of
102 cells per image of four or five images per sample. Briefly, the software was
used to first segment lipid raft staining areas within each cell and then perform
the colocalization analysis on each pixel within these areas.

Detergent resistant membrane (DRM) isolation
SET-2 cells (12.5 X 106) were washed 3X with chilled PBS and lysed in
250 uL of 0.75% Triton X-100 in TNE (25 mM Tris pH 7, 150 mM EDTA, 1 mM
DTT, 150 mM NaCl) plus protease and phosphatase inhibitors (1 mM sodium
vanadate, 10 ug/mL leupeptin, 2 mM sodium pyrophosphate, 2 ug/mL aprotinin,
1 mM phenylmethylsulfonyl fluoride) and incubated on ice for 5 minutes. Cell
lysate was sonicated three times for 10 seconds each (FS60 Fisher Scientific

55

Sonicator, Thermo Scientific). Two hundred uL of lysate was added to 400 uL of
60% OptiPrep™ (Sigma-Aldrich) in TNE buffer, and this mixture was loaded into
ultra clear ultracentrifuge tubes. Lower density OptiPrep™ solutions were loaded
on top of 40% layer in decreasing order, 35%, 30%, 25%, 20% and 0%, final
volume of 600 uL per layer. Samples were spun at 20,000 X g for 20 hours at
4ºC (Beckman Coulter Optima L-90K ultracentrifuge). Fractions (600 uL) were
then removed from top to bottom of each gradient.

GM1 dot blots
Aliquots (5 uL) of each gradient fraction were dotted on nitrocellulose
membrane, allowed to dry, and the membrane was washed with PBS.
Membranes were blocked in 5% non-fat dry milk/PBS for 30 minutes at RT. GM1
detection in dot blots was performed using horse radish peroxidase conjugated
cholera toxin-B (CTB) (Sigma-Aldrich, C3741) at a 1:10,000 dilution in 5% nonfat dry milk/PBS, and incubated o/n at 4ºC. Dot blots were washed 3X with 0.3%
Tween-20/PBS and developed with ECL Plus (Thermo Scientific).

Immunoblotting
For DRM experiments, 50 uL of fractions were analyzed by SDSpolyacrylamide gel (SDS-PAGE). For signaling studies, 2-5 X 106 cells were
washed with chilled PBS and lysed in lysis buffer (25 mM Tris, pH 7.4, 150 mM
NaCl, 25 mM NaF, 1% Triton X-100, plus protease and phosphatase inhibitors).
Lysed cells were centrifuged at 14,500 X g for 5 minutes at 4ºC. Protein
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concentration was determined using Pierce BCA reagent (Thermo Scientific) and
lysates run on SDS-PAGE. Primary antibodies utilized for immunoblotting
include: JAK2 (Cell Signaling, #3230), phospho- (P-) JAK2 (pY-1007/1008; Santa
Cruz, sc-16566), P-STAT5 (pY694; BD Transduction, #611964), STAT5 (Santa
Cruz, sc-835), Hsp90 (Santa Cruz, sc-7947), P-ERK (pT202/Y204; Cell
Signaling, #4370), ERK (Santa Cruz, sc-93), P-AKT (pS473; Cell Signaling,
#4060), AKT (Santa Cruz, sc-8312), and Flotillin-1 (Cell Signaling, #3253).
Secondary antibodies were from Thermo Scientific. Immunoprecipitation
experiments were done using JAK2 antibodies (Cell Signaling, #3230) and
Protein-A agarose (Thermo Scientific). All blots were developed using West Pico
Chemilluminescence, ECL Plus, or Super Signal West Femto
Chemilluminescence (Thermo Scientific).

Cell growth curves
HEL or SET-2 cells were plated at 0.15 or 0.2 X 106 cells/mL and treated
with DMSO or simvastatin (Sigma-Aldrich, #S6196). DMSO content was kept
constant at 0.1% for all samples. Total cells and viability were determined by
trypan blue exclusion.

Annexin V staining
HEL cells (1 X 106) were treated with 1 or 5 uM simvastatin for 24 and 48
hours. Cells were washed with PBS and resuspended in 100 uL 5% BSA in PBS.
Fifty uL of cells were added to 50 uL 2X Annexin V Binding Buffer (BD
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Pharmingen) and 11 uL staining solution (8 uL of 10ug/mL propidium iodide (BD
Pharmingen) plus 3 uL Annexin V-FITC (BD Pharmingen). Cells and staining
solution were incubated for 15 minutes at RT, followed by addition of 300 uL of
1X Annexin V Binding Buffer. Samples were analyzed by flow cytometry.

Cholesterol measurement
Cells (2 X 106) were treated with 1 or 5 uM simvastatin for 96 hours. Nonviable cells were removed by ficoll centrifugation. Cholesterol was measured
using Amplex Red Cholesterol Assay kit (Life Technologies), per manufacturer’s
directions. Fluorescence was measured on a Synergy HT fluorometer (Biotech
Instruments, Inc) using 560/590 excitation/emission settings.

Colony formation assay
Peripheral blood mononuclear cells (MNCs) were isolated by ficoll
separation. Cells (0.5 - 1 X 105) were then plated in methylcellulose containing
rhSCF, rhIL-3, and rhGM-CSF (Stem Cell Technologies, #H4534), with DMSO
(0.1%) or 5 uM simvastatin. For healthy controls, Epo was included at 3 U/mL.
Cells were incubated for 12 days at 37º C with 5% CO2. Burst-forming erythroid
(BFU-E) colonies were enumerated. All patients samples were obtained and
utilized under informed consent through a Moffitt Cancer Center Scientific
Review Committee approved protocol.
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Chapter 3
Analysis of the Mechanism of Action of Statins in JAK2V617F-dependent
Cells

Introduction
Statins are a class of drugs used to treat hypercholesteremia because
they inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol
biosynthesis. Statins have made profound impacts on improving the morbidity
and mortality of cardiovascular disease [134, 223-227]. Statin drugs are well
tolerated by patients and are safe and affordable [168]. As of 2012, there were
seven statins on the market and include both synthetic and naturally
(fermentation) derived compounds. These statins include: atorvastatin
(synthetic), fluvastatin (synthetic), pitavastatin (synthetic), rosuvastatin
(synthetic), lovastatin (naturally derived), simvastatin (naturally derived), and
pravastatin (naturally derived) [136]. Although the complete mechanism by which
statins lower cardiovascular risk remains to be determined [153], many groups
have contributed insight into the complex actions of statins in the cardiovascular
setting. In general, statins have been shown to reduce cholesterol [228], inhibit
protein prenylation, induce vascular remodeling through inhibition of NFkB and
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matrix metalloproteinases [229], and elicit anti-inflammatory effects by modifying
C-reactive protein, tumor necrosis factor-alpha, serum amyloid A, and brain
natriuretic peptide levels [153, 230-232]. Importantly, statins have been shown to
block growth and induce apoptosis of multiple types of cancer cells in vitro and in
vivo [153], including; glioma, melanoma, prostate cancer, neuroblastoma, and
leukemia [172, 217, 233-237]. Our recent studies, described in Chapter 2,
demonstrated that statins have a selective cytotoxic effect in JAK2-V617F-driven
MPN model cells.
Our novel findings implicated cholesterol-rich lipid rafts as having a
potentially important role in the dysregulated JAK2/STAT5 signaling induced by
the JAK2-V617F mutant, suggesting lipid rafts may serve as a platform for
signaling complexes required for JAK/STAT signaling. Our work has shown that
cholesterol-lowering statins are cytotoxic and thus growth inhibitory in JAK2V617F-driven cell lines and primary MPN cells [238]. We had aimed to disrupt
lipid rafts with cholesterol-lowering statins by targeting cholesterol biosynthesis
and thus deregulating a crucial component of lipid rafts. However, HMG-CoA
reductase inhibition by statins could have multiple effects in cells (i.e. inhibition of
protein prenylation and, or lowering cellular cholesterol), since this enzyme is an
early component in the mevalonate pathway. Thus, it is plausible that cholesterol
biosynthesis may not be the only or the actual cause of the cytotoxic effects
induced by statins in JAK2-V617F driven cells.
In this study, we analyzed the mechanism of action driving the cytotoxic
effects induced by statins in JAK2-V617F-driven cells. We demonstrate that

60

multiple components of the mevalonate pathway are affected by statin treatment
in MPN cells including: cholesterol levels, geranylgeranylation, and farnesylation.
In addition, we show that JAK2 localization in rafts, and EpoR glycosylation are
also altered upon statin treatment of MPN model cells. We have systematically
assessed the mevalonate pathway end products that may contribute to the
cytotoxic effects in JAK2V617F-driven cells. Our results suggest a likely
requirement of multiple components of the mevalonate pathway for JAK2-V617Fdriven cell growth.

Results
Assessing the contribution of cholesterol in statin-induced effects on
JAK2V617F-dependent cells
We began analyzing the mechanism of action driving the cytotoxic effects
of statins by assessing the cholesterol levels after treatment with cholesterollowering statins. Multiple statins at 1 and 5 µM doses were effective at reducing
the cholesterol levels in HEL cells. A reduction in cholesterol was seen after 96
hours of treatment by simvastatin (sim), lovastatin (lov), and atorvastatin (ator)
compared to the DMSO control in HEL cells (Figure 14). Specifically, we found
an 18.3% (1 µM sim), 37.8% (5 µM sim), 16.8% (1 µM lov), 46.9% (5 µM lov),
46.9% (1 µM ator), and 41.2% (5 µM ator) reduction in cholesterol compared to
the DMSO control in HEL cells (Figure 14).
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Cholesterol add-back after statin treatment in JAK2-V617F-driven cells
We next performed add-back experiments in order to determine if
cholesterol addition could restore cell growth and viability after simvastatin
treatment. We supplemented our cell cultures with Synthechol, a synthetic
cholesterol, and assessed viable cell numbers over time by trypan blue
exclusion.
There was a minor degree of cytotoxicity associated with 0.1X and 1X cholesterol
add back itself to SET-2 cells when compared to DMSO control.

Fluorescence
Units
(Relative
Cholesterol)

Figure 14: Statins reduce cholesterol in HEL cells. (A) A fluorescentbased cholesterol assay was used to measure cholesterol in HEL cells
that were treated with 1 or 5 µM statin (simvastatin (sim), lovastatin (lov),
or atorvastatin (ator)) for 96 hours. (B) The percent cholesterol reduction
compared to DMSO-treated cells is graphed. Low dose statins (1 and 5
µM) were able to reduce cellular cholesterol compared to the DMSO
control.
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However, we found a partial restoration in total viable SET-2 cell numbers
over time with the addition of cholesterol during 5 µM simvastatin treatment
(Figure 15A). The % viability of SET-2 cells treated with 5 µM sim was slightly
greater after two days of cholesterol treatment, while after four days of treatment
the % viability was not enhanced (Figure 15B). Cholesterol addition in HEL cells
was toxic so we were unable to utilize these cells for these analyses (data not
shown).

Evaluating the effects of statins on lipid rafts and JAK2 localization in lipid rafts
Our previous studies showed that lipid raft disrupting agents such as
MBCD (methyl-beta-cyclodextrin) and filipin complex, downregulated
JAK2/STAT5 signaling in cell lines that were dependent on the transforming
JAK2-V617F mutant (Chapter 2) [238]. To address the potential of statins to
disrupt lipid rafts in JAK2-driven cells, we evaluated the effect of atorvastatin on
lipid raft integrity in SET-2 cells. Detergent resistant membranes (DRMs) were
isolated using a gradient-ultracentrifugation technique. DRMs were assessed by
dot blot analysis, detecting GM1, a lipid raft-associating lipid using cholera toxinHRP as a probe. Separation between the upper and lower fractions suggests that
the lower buoyant density lipid rafts separated from the higher buoyant density
whole cell lysate.
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Figure 15: Cholesterol add back partially restores the cytotoxic
effects induced by simvastatin in SET-cells. (A) SET-2 cells were
treated with 0 (DMSO), 5 µM simvastatin (sim), 1X cholesterol, or 5 µM
sim with 1X cholesterol and counted every two days by trypan blue
exclusion. Addition of 5 µM sim and 1X cholesterol resulted in a partial
increase in viable cell numbers compared to the 5 µM sim treatment
alone. (B) The viability of SET-2 cells was assessed after 5 µM sim and
cholesterol addition and compared to DMSO control and 5 µM sim alone.
Cholesterol addition with 5 µM sim slightly enhanced the viability at Day 2
compared to the 5 uM sim alone sample. At day 4, no restoration in
viability was seen under the same conditions. Experiments were
replicated three times. Error bars indicate standard deviation and p value
was calculated using T-test (GraphPad Prism, Inc.).
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We found that 5 µM atorvastatin did not disrupt lipid rafts as shown by the
detection of GM1 in the low buoyant density raft fraction (primarily fraction 2),
which is separated by fractions 3 and 4, making fractions 5 and 6 the non-raft
fractions (Figure 16A). In support of the dot blot data, we analyzed Flotillin-1, a
resident raft protein, by western blot and detected Flotillin-1 in the lower buoyant
density fractions (2 and 3) in the 5 µM ator treated SET-2 cells, similar to the
DMSO control (Figure 16B), suggesting there was no noticeable disruption in
lipid rafts (Figure 4B). Nevertheless, when assessing the expression of JAK2
across the fractions, we did find less JAK2 in the DRM (fraction 2 and 3) in the 1
and 5 µM ator treated SET-2 cells compared to the DMSO control (Figure 16B).
This suggests JAK2 protein localization within DRMs had been affected by statin
treatment. Similar results were seen with 5 µM simvastatin in SET-2 cells (data
not shown). We previously reported that statins reduced the localization of JAK2V617F and lipid rafts as shown by immunofluorescence (Chapter 2) [238], but did
not significantly reduce lipid raft aggregates, which is in support of our raft
fractionation data showing atorvastatin did not fully disrupt lipid rafts but lowered
JAK2-V617F detection in the lipid raft fractions (Figure 12).

Mevalonate restores the cytotoxic effect of statins in JAK2-V617F-driven cells
To address the multiple end products, aside from cholesterol, in the
mevalonate pathway, we performed add back experiments with intermediates of
the mevalonate pathway to simvastatin treated JAK2-V617F-driven cell lines and
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Figure 16: Atorvastatin alters JAK2 localization in detergent resistant
membranes. (A) SET-2 cells were treated with 0 (DMSO), 1, or 5 µM
atorvastatin (ator) for 96 hours and were analyzed similarly to the experiment in
Figure 8A by density gradient separation, where lower buoyant density raft
fractions were separated from higher buoyant density non-raft fractions. Dot
blot analysis demonstrates GM1 detection in fraction 2 in DMSO control, with
GM1 detected in fraction 2 in the 5 µM ator sample, suggesting lipid rafts were
not fully disrupted. (B) Western blot analysis from gradient fractionation lysates
was performed similarly to experiment in Figure 8B. Total JAK2 and Flotillin-1
were blotted, as indicated. Flotillin-1, a resident raft marker, is detected in lower
buoyant density raft fractions (2-4), suggesting lipid rafts were not fully
disrupted. However, reduced JAK2 is detected in the 5 µM ator sample,
suggesting alteration of JAK2 localization in lipid rafts.
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assessed the effects on the total viable cell numbers over time. We started with
an early intermediate in the mevalonate pathway, mevalonate, which is the
product of HMG-CoA reductase reducing HMG-CoA (refer to Figure 6).
Mevalonate (100 µM) restored the total viable cell number of HEL cells treated
with 1 and 5 µM sim (Figure 17).

Assessing the role of farnesylation in statin action in targeting JAK2-V617Fdriven cells

Further downstream the pathway is the end product, farnesyl. The first
method we employed to detect potential inhibition of farnesylation involved
probing samples for cleavage of HDJ-2, a protein that is exclusively farnesylated.
Western blot analyses of HDJ-2 can distinguish the farnesylated form (lower
molecular weight, ~44 kDa) and the unfarnesylated form (~49 kDa) of HDJ2.
Inhibition of farnesylation results in an increase in the presence of the upper
band and thus results in a double band by western blot due to detection of the
unfarnesylated HDJ-2 protein. Higher doses (5 µM or higher) of sim or lov
displayed a minor induction of the unfarnesylated HDJ-2 protein band, while both
1 and 5 µM ator displayed a single band for HDJ-2, suggesting little to no
inhibition of farnesylation (Figure 18A). As a positive control for farnesylation
inhibition, we treated HEL cells with 1 µM FTI-2153 for 48 hours and assessed
HDJ-2 by western blot. The HDJ-2 doublet validated that farnesylation was
inhibited (Figure 18A).
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Figure 17: Mevalonate restores cytotoxic effects induced by simvastatin
in HEL cells. HEL cells were treated with 0 (0.1% DMSO and 0.1%
methanol), 100 µM mevalonate (Mev), and 1 or 5 µM simvastatin (sim) alone,
or in combination with 100 µM Mev were counted every two days using trypan
blue exclusion. Mev prevented the cytotoxic effect of sim treatment. Data
represents a single experiment that was replicated three times.

To investigate the possibility that farnesylpyrophosphate (FPP) could
restore the minor inhibition on farnesylation we detected with 5 µM simvastatin
and 5 µM lovastatin, we treated HEL cells with 5 µM simvastatin and 10 µM FPP
for 48 hours and assessed HDJ-2. Western blot analyses showed that FPP did
restore HDJ-2 farnesylation as demonstrated by the single HDJ-2 band (Figure
18B), suggesting FPP is functional and warrants use in studies that aim to
reverse the cytotoxic effects of simvastatin.

Farnesylpyrophosphate does not readily restore viable cell numbers after statin
treatment in JAK2-V617F-driven cell lines
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Although we detected only a minor inhibition of farnesylation after
simvastatin treatment, we sought to rule out the possibility that statins cytotoxic
actions were due to targeting farnesylation to any extent. To restore the defect in
farnesylation we added back farnesylpyrophosphate (FPP) to HEL cells treated
with 5 µM simvastatin and found there to be a partial restorative effect on total
viable cell numbers (Figure 19A) and viability over time (Figure 19B), suggesting
that FPP does not readily prevent the cytotoxic effects on viable cell numbers
and viability induced by 5 µM simvastatin in HEL cells.

Effects on geranylgeranylation after statin treatment in JAK2-V617F-driven cells
To investigate components further downstream of FPP in the mevalonate
pathway, we assessed the state of geranylgeranylation after statin treatment in
HEL cells. We used Rap1A protein as a tool to gauge geranylgeranylation, for it
is exclusively geranylgeranylated. Using an antibody that recognizes the Rap1A
carboxy terminus, which gets cleaved after geranylgeranylation, and thus this
antibody only recognizes unprenylated Rap1A protein. We demonstrated that
sim, lov, and ator induced the accumulation of unprenylated Rap1A. This
demonstrated clear inhibition of geranylgeranylation. As a control to induce
unprenylated Rap1A protein, we utilized the geranylgernanyl transferase inhibitor
GGTI-2417 (Figure 20A). Furthermore, we reversed the inhibition on
geranylgeranylation with geranylgeranylpyrophospahte (GGPP) as shown by
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Figure 18: Statins induce a minor inhibition on farnesylation in HEL
cells. (A) HEL cells were treated with 0 (DMSO), 1 or 5 µM simvastatin (sim),
lovastatin (lov), or atorvastatin (ator) for 48 hours. Western blot analysis of
HDJ-2, a protein that is exclusively farnesylated, showed that statins induced
minor inhibition of farnesylation as shown by the appearance of the double
band (unprenylated and prenylated HDJ-2). HEL cells were also treated with
1 µM FTI-2153 (farnesyl transferase inhibitor) as a positive control for
inhibition of farnesylation. (B) Western blot analysis of HEL treated with
farnesylpyrophosphate (FPP) and 5 µM sim for 48 hours demonstrated
restoration in HDJ-2 farnesylation (single band indicates active farnesylation),
suggesting FPP add back does restore minor farnesylation defects induced
by sim.
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Figure 19: Farnesylpyrophosphate (FPP) partially restores cytotoxic
effects induced by simvastatin in HEL cells. (A) HEL cells were treated with
0 (DMSO), 5 µM simvastatin (sim), and 10 µM FPP alone or in combination
with 5 µM sim and counted with trypan blue. FPP addition with 5 µM sim
resulted in a slight restoration in total viable HEL cells over time. (B) The
viability of growth curve samples was analyzed (# of live cells/# of total cells)
and showed that FPP in combination with 5 µM sim partially restored cell
viability compared to 5 µM sim alone. Error bars represent standard deviation
and p value calculated using T-test (GraphPad Prism, Inc.). Experimental data
represents a single experiment which was replicated three times, with
replicates supporting presented data.
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western blot analysis of Rap1A in HEL cells treated with 5 µM simvastatin and 10
µM GGPP for 48 hours (Figure 20B).

GGPP partially restores total viable HEL cells treated with simvastatin after 48
hours of treatment, with loss of any restorative effect at 96 hours
To determine if the inhibition of geranylgeranylation was responsible for
statin’s cytotoxic effects, we performed experiments adding back geranylgeranyl
pyrophosphate (GGPP) to statin treated HEL cells and assessed viable cell
numbers over time. Interestingly, GGPP could not restore cell growth (Figure
21A). However, the viability of HEL cells treated with simvastatin was restored
after 48 hours of treatment with GGPP add back, but at the 96 hour time point
and beyond, no restorative effect was observed (Figure 21B).

Assessing the role of combined prenylation defects in statin action in targeting
JAK2-V617F-driven cells
To address the effects on combined prenylation, both farnesylation and
geranylgeranylation, after statin action in JAK2-V617F-driven cells, we performed
add back experiments restoring GGPP and FPP simultaneously and used trypan
blue exclusion analysis to determine viable cell numbers. The combination of 10
µM GGPP and 10 µM FPP co-cultured with 5 µM simvastatin treated HEL cells
did not improve total viable cell numbers compared to the 5 µM simvastatin and
10 µM FPP treated sample, or the 5 µM simvastatin and 10 µM GGPP sample
(Figure 22).
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Figure 20: Statins inhibit geranylgeranylation in JAk2-V617F-dependent
cells. (A) HEL cells were treated with 0 (DMSO), 1 or 5 µM simvastatin
(sim), lovastatin (lov), or atorvastatin (ator) for 48 hours and analyzed by
western blot to assess inhibition of geranylgeranylation by probing with an
antibody that recognizes the carboxy terminus of Rap1A, which gets cleaved
after geranylgeranylation. We treated HEL cells with 10 µM GGTI-2417
(geranylgeranyl transferase inhibitor) for 48 hours, as a positive control for
geranylgeranylation inhibition (presence of band indicates inhibition). Sim,
lov, and ator inhibited geranylgeranylation. Hsp90 was detected as a loading
control. (B) To test if the inhibition on geranylgeranylation could be reversed
with geranylgeranylpyrophosphate (GGPP), we ran western blot analysis of
HEL cells treated with 0 (DMSO), 5 µM sim alone, and 10 µM GGPP alone or
in combination with 5 µM sim and by probing for Rap1A. GGPP restored the
inhibition of geranylgeranylation induced by simvastatin. Actin was detected
as a loading control.
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Figure 21: GGPP addition can not restore HEL cell growth and viability
following simvastatin treatment. (A) HEL cells were treated with 0 (DMSO),
5 µM simvastatin (sim), 10 µM GGPP, alone or in combination with 5 µM sim
and counted with trypan blue. GGPP does not restore viable HEL cell numbers
over time. (B) Analysis of the viability of HEL cells treated with sim, GGPP
alone, or in combination demonstrated that viability was restored at short-time
points (Day 2), but restorative effect was lost at later time points (Day 4). Error
bars represent standard deviation of duplicate samples. Data represents
experiments that were run a minimum of three times.
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Figure 22: Restoration of prenylation in simvastatin treated HEL cells
does not restore viable cell numbers. HEL cells were treated with 0
(DMSO), 5 µM simvastatin (sim), 10 µM GGPP, and 10 µM FPP alone and in
combination as indicated, and counted with trypan blue. Add back of both
prenylation end products, FPP and GGPP, did not restore viable cell numbers
when compared to the 5 µM sim and DMSO controls. This suggests that
overall prenylation may not be solely responsible for the cytotoxic effects
induced by sim. Data represents a single experiment that was run in triplicate.

The effect of simvastatin on EpoR glycosylation
Hamadmad et al. previously reported lov treatment at short-time points
could downregulate surface expression of EpoR in ASE2, an erythroleukemia cell
line [203]. Hamadmad et al. demonstrated that lov treatment inhibited
geranylgeranylation and dolichol, a downstream intermediate off of the
geranylgeranyl branch of the mevalonate pathway involved in N-linked
glycosylation with proteins like EpoR (refer to Figure 6). Furthermore, due to
EpoR potentially playing an important role in PV and because JAK2-V617F
requires a homodimeric cytokine receptor to function, we questioned if
simvastatin and its ability to inhibit geranylgeranylation, affected EpoR
glycosylation. After treating HEL cells with 5 µM simvastatin for 48 hours, we
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found a difference in the expression pattern of EpoR by western blot analysis.
HEL cells treated with DMSO control displayed a two-band protein banding
pattern with a ~66 kDa (mature, fully gycosylated form) and ~64 kDa (maturing
form) band (Figure 23; lane 1), while the 5 µM sim treated sample displayed a
prominent ~64 kDa (maturing form of EpoR) with possible breakdown products of
EpoR between 34 and 43 kDa (Figure 23; lane 3). We have confirmed that the
~66kDa form is fully gylcosylated because of its resistance to deglycosylation by
EndoH (data not shown), a characteristic of full glycosylation. The ~66kDa fully
gycosylated form is utilized as a surrogate for plasma membrane localized EpoR
and thus sim treatment appears to inhibit plasma membrane localization of
EpoR. We were also able to confirm that restoring geranylgeranylation with 10
µM GGPP after 5 µM sim treatment in HEL cells did restore the expression of the
~66 kDa EpoR band (mature form) (Figure 23; lane 4).

Discussion
Statin drugs have recently developed an appreciated potential in the treatment of
some cancers including melanoma [239], glioma [240], neuroblastoma [241],
prostate cancer [170, 242-243], and leukemia [234, 244]. We were the first to
report on the anti-neoplastic effects of statins in JAK2-V617F-driven
myeloprolifertaive cell lines and primary MPN samples [238]. The complete
mechanism of action behind statin activity in the hypercholesteremia setting is
still not fully elucidated. Statins have been shown to have a multitude of effects
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Figure 23: Simvastatin alters expression of EpoR gycosylation forms in
HEL cells. HEL cells were treated with 0 (DMSO), 10 µM GGPP, and 5 µM
simvastatin (sim) alone, or in combination with 10 µM GGPP for 48 hours and
were analyzed by western blot to assess EpoR expression. Sim treatment
promoted an accumulation of the 64 kDa EpoR form (partially glycosylated, still
maturing form) whereas, the DMSO control displayed the fully glycosylated EpoR
(~66 kDa) and the maturing EpoR form (64 kDa), suggesting sim blocked EpoR
from becoming fully glycosylated. Sim also induced potential breakdown products
of EpoR with detection of multiple bands ranging in molecular weights from ~2056 kDa. To test the effects of reduced GGPP and subsequent loss of dolichol,
GGPP was co-cultured with 5 µM sim treated HEL cells for 48 hours and
analyzed by western blot to investigate EpoR glycosylation isoforms. GGPP
restored the fully glycosylated EpoR isoform (~66 kDa).
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that contribute to lowering cholesterol in cardiovascular risk patients [134, 153,
224, 226-227]. Variability of statin action can be influenced by cell type, disease
type, type of statin, dosage, and duration of treatment [245]. In this work, we
further investigated the statin mechanism of action in the setting of JAK2-V617Fdriven transformation. Indeed, 1 and 5 µM doses of all statins tested (sim, lov,
and ator) that induced cytotoxic effect in JAK2-V617F-driven cell lines reduced
cholesterol to variable capacities depending on the statin and dose. Since our
previous work showed a dependence of JAK2-V617F signaling on lipid rafts, we
initially chose to treat the JAK2-V617F-dependent MPN model cell lines with
statins in an attempt to alter lipid rafts, which are rich in and are dependent on
cholesterol. Statins, like lipid raft disrupting agents we hoped would alter plasma
membrane cholesterol and hence disrupt lipid rafts, the site where JAK2-V617F
protein complexes may be located. Although our data did not provide evidence
that 5 µM ator disrupted lipid rafts, we did find decreased JAK2 protein in the raft
fractions, suggesting that JAK2 protein and lipid raft co-localization was
disrupted. Considering the percentage of cholesterol reduction after atorvastatin
treatment (46% reduction after 96 hours of treatment), in comparison to lipid raft
disrupting agents, which are thought to drastically alter cholesterol, statins may
not disrupt lipid rafts enough to the level of detection in the lipid raft isolation
assay. Nonetheless, we demonstrate evidence for an alteration in JAK2 protein
localization with lipid rafts, but no direct evidence for lipid raft disruption by
atorvastatin treatment. Interestingly, cholesterol add back allowed for only a
partial restoration in total viable SET-2 cells over time, suggesting that the
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cholesterol decrease may not be solely responsible for the cytotoxic effects
induced by statins. It is important to note that few reports that attempt to analyze
statin affects by adding back products of the mevalonate pathway ever
demonstrate that cholesterol add back is successful. In fact, personal
communication with other researchers has confirmed that cholesterol addition
can be toxic to cells, as we have seen when elevated cholesterol addition is used
[246]. These results lead us to examining potential effects on end products other
than cholesterol in the mevalonate pathway.
We first took a step back and added an early intermediate of the
mevalonate pathway, mevalonate itself. Mevalonate is produced by the activity
of HMG-CoA reductase and thus its levels should be decreased following
treatment with statins, which are inhibitors of HMG-CoA reductase (Figure 17).
Indeed, mevalonate completely rescued the growth inhibitory effects of statin
treatment, demonstrating that, the HMG-CoA reductase inhibitory activity of
statins is responsible for the detrimental effects observed on JAK2-V617F-driven
cell growth (Figure 17).
Since statin treatment clearly inhibited geranylgeranylation (Figure 20) we
also performed GGPP add back experiments. GGPP add back had a slight
restorative effect on the viability of HEL cells in the short-term but not the longterm (Figure 21). Indeed, simvastatin inhibited geranylgeranylation in these
JAK2-V617F-driven cells, but GGPP add back could not restore growth,
suggesting that inhibition of geranylgeranylation is not solely responsible for the
cytotoxic effect induced by simvastatin. Perhaps the initial cell death induced by
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simvastatin is due to geranylgeranylation inhibition but additional effects of
inhibiting the mevalonate pathway cannot be overcome by GGPP, and this leads
to the inability of GGPP to restore long-term growth and viability. This is not
inconsistent with other published work, which suggests GGPP add back can
rescue the effect of statin treatment. Such data are generally always presented
as short-term experiments and never address long-term effects such as the
ability to restore cell growth. Additionally, simvastatin elicits a minor inhibition of
farnesylation (Figure 18). Combination add back of the isoprenoid intermediates
FPP and GGPP, was also unable to fully restore cell growth and viability after
simvastatin treatment, suggesting statin’s cytotoxic effect is not based on
inhibiting prenylation alone. However, the inhibition of geranylgeranylation was
shown to be responsible for the redistribution of the glycosylated forms of EpoR,
shifting the EpoR protein population to the immature glycosylated isoform.
Adding back GGPP restored fully processed/glycosylated (plasma membrane
localized) EpoR (Figure 23). Since JAK2-V617F requires a cytokine receptor for
signaling, this could be a mechanism by which statins may affect JAK2-V617F
signaling, that is, statins may regulate the processing and subsequent plasma
membrane localization of a requisite cytokine receptor. However, in the cell lines
we have utilized, the specific requirement for EpoR remains unknown, but it is
possible the glycosylation of other receptors may be similarly affected by statin
treatment. Because mevalonate completely protected cells from the effects of
statin treatment (Figure 17), we conclude that the effects of statins are indeed
due to its inhibition of the mevalonate pathway. However, since isoprenoid
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intermediate add back did not protect cells from the effects of statin treatment, it
is likely that inhibition of other pathways or a combination of pathways that are
dependent on products of the mevalonate pathway are responsible for the effect
of statins on JAK2-V617F-driven cell growth.
In summary, we have shown statins affect multiple components of the
mevalonate pathway, including inhibition of cholesterol biosynthesis,
geranylgeranylation, and a minor inhibition of farnesylation, in MPN model cells
that are dependent on JAK2-V617F. Statins presumably inhibit the various end
products of the mevalonate pathway and induce a variety of cellular changes.
These changes may no longer be reversible or occur at a rate that is not
compatible with add back of the end products, as we were unable to identify a
single end product whose inhibition could be determined to elicit the effects of
statin treatment. While the exact mechanism by which statins induce its cytotoxic
effects on JAK2-V617F-positive MPN model cells remains to be elucidated, it is
clear that these cells are sensitive to statins by undergoing apoptosis which
results in decreased cell growth. This suggests statin treatment may be an option
to incorporate into future therapies for MPNs, including possible combination with
JAK2 inhibitors.

Materials and Methods
Growth curves
HEL or SET-2 cells were plated at a concentration of 0.1 – 0.25 X 106
cells/mL and treated with 0 (DMSO), and 1 or 5 µM simvastatin (Sigma-Aldrich
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#S6196). 1X synthechol (Sigma-Aldrich # S5442), 100 µM mevalonate (SigmaAldrich #79849), 10 µM FPP (Sigma-Aldrich # 6892), and 10 µM GGPP (SigmaAldrich #G6025) were added alone, or in combination (DMSO content maintained
at 0.1% across all samples) and cell counts and viability were assessed every
two days using trypan blue. Cell cultures were passed every two days with
replenishment of additive lipid compounds, ensuring the stability of these lipids is
not a concern in the experiments.

Cholesterol assay
Cholesterol was measured using Amplex Red Reagent as described in
Chapter 2 [238]. Briefly, 2 – 3 X 106 cells were treated with 0 (DMSO), 1 or 5 µM
simvastatin (Sigma-Aldrich #S6196), lovastatin (Sigma-Aldrich #M2147), or
atorvastatin (Sigma-Aldrich #PZ0001) for 96 hours. Cells were washed with 1X
RT PBS three times and ficolled with lymphocyte separation media (Corning #25072-CV) to remove dead cells. Amplex Red Cholesterol Measurement kit
(Invitrogen #A12216) was used to measure cholesterol as manufacture
recommends. Fluorescence was measured using Synergy HT fluoremeter
BioTek Inc. Winooski, VT, USA) using 560/590 excitation/emission settings.

Western blot
2 – 5 X 106 cells were washed with 4ºC 1X PBS and lysed in 4ºC lysis
buffer (25 mMTris, pH=7.4, 150 mM NaCl, 25 mM NaF, 1% Triton-X-100, and
protease inhibitors). Cell lysate was centrifuged at 14.5 X 105 X g for 5 minutes at
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4ºC. Pierce BCA reagent (Thermo Scientific) was used to determine protein
concentration. Protein lystaes were run on SDS-PAGE (8 - 12.5% gels). Primary
antibodies included: total JAK2 (Cell Signaling Technology #3230), Rap1A
(Santa Cruz #sc-1482), HDJ-2 (Neomarker #AM00209PU-N), Hsp90 (Santa Cruz
#sc-7947), actin (Sigma #AC-74), EpoR (Amgen A82), Flotillin-1 (Cell Signaling
Technologies #3253), and CTB-HRP (Sigma-Aldrich #C3741). Secondary
antibodies were from Thermo Scientific. West Pico Chemilluminescence, ECL
Plus, or West Femto Chemilluminescence were used to develop western blots.
DRM dot blot and western blot analyses performed in same fashion as described
in Chapter 2 [238].
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Chapter 4
Statins cooperate with JAK inhibitors to enhance the killing effect on JAK2V617F-driven cells

Introduction
The classical MPNs including polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF), are hematopoietic stem
cell disorders characterized by expansion of the myeloid lineage in one form or
another [186]. Dysregulated JAK/STAT signaling is common to the classical
MPNs [65, 95], with activating mutations found in patients including mutations in
cytokine receptors (i.e. MPL-W515) [78-79], JAK2 (i.e. JAK2-V617F [186], exon
12 mutations [74]) as well as inactivating mutations in negative regulators of
JAK/STAT signaling (e.g. SOCS1, LNK, etc.) [64].
The JAK inhibitor, ruxolitinib (Incyte, INCB018424) was recently approved
for the treatment of MF in November of 2011. Ruxolitinib induced a marked
reduction in splenomegaly and reduced in constitutional symptoms including
fever, fatigue, cachexia, night sweats, anemia, pruitus, and bone pain [247].
However, JAK inhibitors have not been shown to induce partial or complete
remissions, nor have they been shown to reduce allele burden in MF patients
[94, 205], suggesting there is much room for improvement in the treatment of
MPN patients. It is well established that JAK/STAT signaling is defective in MPNs
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[65], and it is plausible that targeting multiple sites in a key, dysregulated
pathway may be necessary to effectively block oncogenic signaling.
We have demonstrated that cholesterol-lowering statins reduce total
viable cell numbers and induced apoptosis in JAK2-V617F-driven cell lines and
inhibit colony formation of primary MPN cells (Chapter 2). In our current study,
we hypothesized that statins will enhance the cytotoxic effect of JAK2 inhibition
on JAK2-V617F-dependent cells. We demonstrate an enhancement of cytotoxic
effects when combining statin therapy with JAK inhibitor therapy in JAK2-V617Fdriven cells. We show statin and JAK inhibitor combination treatment enhances
the reduction in total viable cell numbers and viability over time compared to
single agent treatment alone. Additionally, we show that combination treatment
amplifies the number of cells undergoing apoptosis compared to single agent
treatment. Furthermore, we found that combination treatment led to a G1 arrest
in the cell cycle. Our work is the first to provide evidence that statins drugs
cooperate with JAK inhibitors in JAK2-V617F-driven cells and proposes statins
may enhance JAK inhibitor therapy in patients.

Results
To determine if there is a potential therapeutic advantage to combining
statin treatment with JAK inhibitors, we treated a panel of JAK2-V617F-driven
MPN model cells. These cell lines include HEL (Human Erythroleukemia) cells,
homozygous for the JAK2-V617F mutation, SET-2 cells, heterozygous for the
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JAK2-V617F mutation, and Uke1 cells, homozygous for the JAK2-V617F
mutation [196].

Simvastatin cooperates with JAK Inhibitor I to enhance the reduction in viable
HEL cells
HEL cells treated with simvastatin or JAK Inhibitor I (JI), a pan JAK
inhibitor, were effective at reducing total viable cell numbers as single agents, but
in combination led to an enhanced reduction in total viable cell number over time
(Figure 24A). Calculated fold reductions comparing treated samples to DMSO
control (DMSO total viable cell number/drug-treated sample total viable cell
number = fold reduction) were also graphed (Figure 24B). HEL cells treated with
1 µM sim alone showed no reduction in total viable cells compared to DMSO
control at day 4, whereas 1 µM JI led to a 11.7 fold reduction. Combination of 1
µM sim and 1 µM JI resulted in 17.5 fold reduction in total viable cells. Likewise,
5 µM sim alone resulted in a 1.9 fold reduction at day 4, while combining 5 µM
sim with 1 µM JI led to a 50.9 fold reduction in total viable HEL cells (Figure 24B).
Interestingly, the 1 µM JI sample after eight days of treatment demonstrated
signs of resistance with increases in the total viable cell numbers (Figure 24A).
However, JI combined with only 1 µM simvastatin eliminated resistance from
occurring (Figure 24A).
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Figure 24: Simvastatin cooperates with JAK Inhibitor I in HEL cells to
enhance the reduction in total viable cell numbers. (A) HEL cells were
treated with DMSO (0.1% dimethyl sulfoxide), low dose simvastatin (sim), and
JAK Inhibitor I (JI) alone, and in combination and counted every two days
using trypan blue exclusion. Low dose sim and JI alone reduce total viable cell
numbers, but when combined led to an enhanced reduction in cell numbers
over time. (B) Graph represents total viable cell fold reduction of drug treated
samples compared to DMSO control at day 4 (Equation: (DMSO total viable
cell number/ sample total viable cell number = fold reduction). Experimental
data represents a single experiment which was replicated in SET-2 cells
(Figure 25).
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Simvastatin cooperates with JAK Inhibitor I to enhance the reduction in viable
SET-2 cells
Similarly, in a second JAK2-V617F-dependent cell line, SET-2 cells,
displayed a 2 fold reduction in total viable cell numbers in response to 5 µM
simvastatin treatment after 4 days of treatment (Figure 25A). 5 µM simvastatin
alone, led to a 2 fold reduction, while, 1 µM JI led to a 11.9 fold reduction at day
4. When combined, these two drugs induced a 23.7 fold reduction in total viable
cells after 4 days and this reduction continued to increase over additional days of
culture. Impressively, 5 µM sim with 1 µM JI led to 83 fold reduction in total
viable cells compared to DMSO control (Figure 25B). These data demonstrate
that the cooperative ability of simvastatin and JAK Inhibitor I are not JAK2V617F-positive cell line dependent, as both HEL (Figure 24) and SET-2 (Figure
25) cells responded similarly.

Simvastatin cooperates with INCB018424 to enhance the reduction in viable
HEL cells
To test the potential of a second JAK inhibitor to cooperate with statins,
we tested the effects of the JAK1/2 inhibitor, INCB018424 (424, ruxolitinib)
combined with statin treatment on total viable cell numbers and % viability as
demonstrated by trypan blue exclusion. Concordant with the HEL data, 1 µM
simvastatin combined with 0.25 µM 424 led to a similar decrease in total viable
HEL cell numbers (Figure 26A) (5.6 fold reduction) as 0.5 µM 424
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Figure 25: Simvastatin cooperates with JAK Inhibitor I in SET-2 cells to
enhance the reduction in total viable cell numbers. (A) SET-2 cells were
treated with DMSO, low dose simvastatin (sim), and JAK Inhibitor I (JI)
alone, and in combination and counted every two days using trypan blue
exclusion. Low dose sim and JI alone reduce total viable cell numbers, but
when combined lead to an enhanced reduction in cell numbers over time.
(B) Graph represents total viable cell fold reduction comparing drug treated
samples to DMSO control on day 4. Experimental data represents a single
experiment which was replicated in HEL cells (Figure 24).
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treatment alone (5.9 fold reduction) (Figure 26B). Enhanced fold reductions were
seen when combining 1 µM sim (1.6 fold reduction alone) with 0.5 µM 424 (5.9
fold reduction alone), resulting in a 10.9 fold reduction in viable cells. Enhanced
growth inhibition of the culture was especially apparent in later time points of the
experiment (e.g. day 10).
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Figure 26: Simvastatin cooperates with INCB018424 in HEL cells to
enhance the reduction in total viable cell numbers. (A) HEL cells were
treated with low dose simvastatin (sim) or INCB018424 (424) alone, or in
combination and were counted every two days using trypan blue. Combination
treatment of sim and 424 lead to an exaggerated reduction in total viable cell
numbers over time, in a dose-dependent manner. (B) Replicate growth curve to
26A.
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Figure 26 (continued): Simvastatin cooperates with INCB018424 in
HEL cells to enhance the reduction in total viable cell numbers.
(C)Graph represents total viable cell fold reduction of drug treated samples
compared to DMSO control on day 4. Experimental data represents a
single experiment which was replicated in SET-2 cells (Figure 27), and
multiple statins (Figure 28 & 29), with replicates supporting presented
data.
Simvastatin cooperates with INCB018424 to enhance the reduction viable SET-2
cells
SET-2 cells displayed similar enhanced cytotoxic effects with the
combination of simvastatin and INCB018424 treatment as shown by the
reduction in total viable cell numbers (Figure 27A). SET-2 cells treated with 1 µM
sim resulted in a subtle 1.4 fold reduction in viable cells at day 4, while 0.25 µM
424 led to a 3.1 fold reduction. Combining 1 µM sim with 0.25 µM 424 gave rise
to an enhanced 5 fold reduction at day 4. Again, combining 1 µM sim with 0.5 µM
424 (4.5 fold reduction with 0.5 µM 424 alone) resulted in an 8.8 fold reduction in
viable cells at day 4 (Figure 27B).
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Figure 27: Simvastatin cooperates with INCB018424 in SET-2 cells to
enhance the reduction in total viable cell numbers. (A) SET-2 cells were
treated with low dose simvastatin (sim) or INCB018424 (424) alone, or in
combination and were counted every two days using trypan blue. Combination
treatment of sim and 424 lead to an exaggerated reduction in total viable cell
numbers over time, in a dose-dependent manner. (B) Graph represents total
viable cell fold reduction of drug treated samples compared to DMSO control
at day 4. Experimental data represents a single experiment which was
replicated in HEL cells (Figure 26), and multiple statins (Figure 28 & 29), with
replicates supporting presented data.
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Lovastatin cooperates with INCB018424 to enhance the reduction in viable HEL
cells
We next wanted to determine if other statins had similar effects on JAK2V617F-driven growth. We tested the ability of a second statin to cooperate with
INCB018424. We found that lovastatin combined with INCB018424 also
exaggerated the reduction in total viable HEL cell numbers (Figure 28A). 1 µM
lovastatin led to a 1.6 fold reduction in total viable cell numbers, while 0.25 or 0.5
µM 424 led to a 2.8 or 5.9 fold reduction. Combining 1 µM lov with either 0.25 µM
or 0.5 µM 424 resulted in an enhanced 5.6 or 7.5 fold reduction, respectively
(Figure 28B).

Atorvastatin cooperates with INCB018424 to enhance the reduction in viable
HEL cells
We investigated the potential cytotoxic effects of a third statin. Atorvastatin
and INCB018424 combination treatment yielded an enhanced reduction in total
viable cell numbers compared to single agent treatment (Figure 29). 1 µM
atorvastatin led to a 2.3 fold reduction, while 0.25 µM 424 led to a 2.8 fold
reduction in viable cell numbers at day 4. Combination treatment of 1 µM
atorvastatin and 0.25 µM 424 resulted in a 5.4 fold reduction in viable cell
numbers (Figure 29C).
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Figure 28: Lovastatin cooperates with INCB018424 in HEL cells to
enhance the reduction in total viable cells. (A) HEL cells were treated with
low dose lovastatin (lov) or INCB018424 (424) alone, or in combination and
counted every two days using trypan blue. Lov combined with 424 resulted in
an enhanced reduction in total viable cells. (B) Graph represents total viable
cell fold reduction of drug treated samples compared to DMSO control at day
4. Experimental data represents a single experiment which was replicated with
multiple statins (Figure 26 & 29), with replicates supporting presented data.
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Figure 29: Atorvastatin cooperates with INCB018424 in HEL cells to
enhance the reduction in total viable cell numbers. (A) HEL cells were
treated with low dose atorvastatin (ator) or INCB018424 (424) alone, or in
combination and counted every two days using trypan blue. Ator combined with
424 resulted in an enhanced reduction in total viable cells. (B) Graph
represents total viable cell fold reduction of drug treated samples compared to
DMSO control at day 4. Experimental data represents a single experiment
which was replicated using multiple statins (Figure 26 & 28), with replicates
supporting presented data.
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Statins cooperate with INCB018424 to enhance apoptosis in JAK2-driven cells
To assess the effects of simvastatin and INCB018424 combination
treatment on apoptosis, we analyzed the Annexin V-positive cell population by
flow cytometry. HEL cells were treated with 1 and 5 µM simvastatin alone and in
combination with 0.25 and 0.5 µM INCB018424 for 24 and 48 hours, and
assessed for Annexin V binding. Combination treatment of simvastatin and
INCB018424 gave rise to an even greater percentage of the cell population that
was positive for Annexin V, compared to single agent treatment (Figure 30A).
This is especially obvious for combination of 5 µM simvastatin and 0.5 µM
INCB018424. Similar results were obtained with atorvastatin and INCB018424
treatment in HEL cells (Figure 30B).

Simvastatin combined with INCB018424 treatment induces a G1 arrest in JAK2V617F-driven cells
To determine the effect of combination treatment with simvastatin and
INCB018424 on the cell cycle in our MPN model cell lines, we stained cells with
propidium iodide (P.I.) and analyzed DNA content by flow cytometry. We
normalized the P.I. values (% of population) for each sample to the DMSO
control by calculating the difference between the DMSO control and each sample
to report the change in the % of cell population in each cell cycle phase (G1, G2,
or S). After 24 hours of treatment we found a 4.22% increase in G2 after 5 µM
simvastatin treatment. 424-treated cells displayed an increase of cells in G1 of
11.77% and 16.47% in the 0.25 and 0.5 µM 424-treated samples, respectively.
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Combination treatment of 5 µM simvastatin with either 0.25 µM 424 or 0.5 µM
424 led to an additional increase in cells arrested in G1 (Figure 31), even though
simvastatin alone did not induce G1 arrest.
% Cell Population Positive for Annexin V
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Figure 30: Statins cooperate with INCB018424 to enhance apoptosis in
JAK2-V617F-dependent HEL cells. (A) HEL cells were treated with simvastatin
(1 and 5 µM sim), or INCB018424 (0.25 and 0.5 µM 424) alone, or in
combination for 24 or 48 hours and stained with Annexin V and analyzed by flow
cytometry. Sim combined with 424 led to an enhanced induction of apoptosis in a
dose and time-dependent manner. Error bars represent standard deviation of
duplicate samples. (B) Combining atorvastatin (ator) with 424 after 24 or 48
hours led to an increase in Annexin V-positive HEL cells in a dose and timedependent manner. Experimental data represents a single experiment which
was replicated and preformed with multiple statins (Figure 30B), with replicates
supporting presented data. P value was calculated using unpaired t-test using
GraphPad Prism software.
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Figure 31: Simvastatin enhances the INCB018424-induced G1 cell cycle
arrest. HEL cells were treated with DMSO, 5 µM simvastatin (sim), or 0.25 or
0.5 µM INCB018424 alone and in combination for 24 hours and stained with
propidium iodide and analyzed by flow cytometry. Combination treatment led
to a dose-dependent increase in cells arrested in G1. Experimental data
represents a single experiment.

Bliss additivity model demonstrates cooperation between simvastatin and
INCB018424
Next, we sought out to define the type of drug cooperation between statins
and INCB018424 treatment in HEL cells. Specifically, we wanted to determine if
the two drugs acted in an additive or synergistic manner. We assessed the
cooperativity between simvastatin and INCB018424 in HEL cells after 72 hours
of treatment using the Bliss additivity model [248]. We created a threedimensional growth inhibition surface that was delineated by the single drug dose
curves (Figure 32A). The Bliss additivity plane was calculated using the equation
Icomb = (IA + IB) – (IA * IB), where Icomb is the theoretical inhibition due to drugs A
and B in combination and IA and IB are the observed inhibition due to each
individual drug. We then calculated the 95% confidence interval and added
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(upper limit) or subtracted (lower limit) this value from the theoretical plane to
relay statistical significance to our observed values. Values above the upper 95%
confidence interval are synergistic and a sum of these values found to be greater
than 1 suggests moderate synergy between two drugs. The sum of our observed
values (Figure 32B, upward cones) was found to be 0.43. Values below the lower
95% confidence interval are antagonistic and a sum of these values found to be
less than -1 suggests moderate antagonism. The sum of these values (Figure
32C, downward cones) was found to be -0.32. All other data points are between
these two planes and are considered additive.
The Bliss value of 0.43 suggests simvastatin cooperates with INCB018424
in an additive manner in HEL cells. However, we did identify potential doses and
combinations that may be synergistic, as well as antagonistic using the lower
95% confidence interval (Figure 32C). We found that the combination of 1.250
µM simvastatin and 0.15 µM INCB018424 showed potential synergism, while
0.3125 µM simvastatin combined with 0.039 µM, 0.15 µM, or 0.625 µM
demonstrated potential antagonism (Figure 32C).

Simvastatin reduces total viable Uke1 cells that persist in the presence of
INCB018424
A recent report by Koppikar et al. has demonstrated that cells dependent
on JAK2-V617F (Uke1 and SET-2 cell lines) can persist in the presence of
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Figure 32: Simvastatin
cooperates with
INCB018424 in an additive
manner. (A) HEL cells treated
with 0 (DMSO) to 20 µM
simvastatin (sim) alone, or in
combination with 0 (DMSO) to
10 µM INCB018424 (424) for
72 hours were analyzed for
cell viability using Promega
CellTiter Glo luminescence.
Graph plots growth inhibition
of sim versus 424. (B) Bliss
additivity model was used to
determine Bliss values. The
plane at 0 represents the
upper 95% confidence
interval. Upward cones
represent statistically relevant
synergistic values, while
downward cones represent
values below the 95%
confidence interval. (C) Bliss
values using lower 95%
confidence interval.
Downward cones represent
statistically relevant
antagonistic values, while
upward cones represent
values above the lower 95%
confidence interval.
Simvastatin cooperates with
424 in an additive manner, as
suggested by the Bliss Value
of 0.43. However, we
identified doses with potential
synergism at 1.25 µM sim and
0.15 µM 424. This experiment
was done with assistance
from Uwe and Lily Rix (Moffitt
Cancer Center).
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INCB018424 [249]. The term persistence is used rather than resistance because
if the INCB018424 is removed from culture for a short period of time and reintroduced, the cells become sensitive to the drug again. We investigated the
effect simvastatin would have on Uke1-Persistent (Uke1-P) viable cell numbers
over time.We created Uke1-P cells by treating Uke1 cells with low doses of
INCB018424 (0.1 µM) and selecting cells that grow out, subsequently increasing
the doses to 1 µM until a population of cells grows in the presence of 1 µM 424.
Sim (5 µM) prevented the outgrowth if Uke-P cells over the course of the 8 day
experiment (Figure 33).

Discussion
It is accepted in the MPN field that activation of JAK/STAT signaling is a
key feature among all classical MPN patients [65]. Inhibitors that target JAK
enzymes have recently been approved to treat MF patients because of the
improved effects on splenomegaly and constitutional symptoms [94, 205],
suggesting benefit in targeting JAKs in patients. Additionally, the COMFORT-1
and 2 JAK inhibitor clinical trials demonstrated that regardless of presence of the
JAK2-V617F mutant, patients responded similarly to ruxolitinib (INCB018424)
[29, 93-95], suggesting again that JAK activity is important in MPNs. More
recently, we were the first to report that statins alone induce cytotoxic effects in
JAK2-V617F-dependent cell lines and primary MPN cells (Chapter 2) [238]. In
our current study, we sought out to determine if JAK inhibitor therapy cooperated
with statin therapy in JAK2-V617F-dependent cells to ultimately identify
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Figure 33: Simvastatin reduces total viable Uke1 cells that persist in the
presence of INCB018424. Uke1 cells were made persistent to 1 µM
INCB018424 (424) by treating Uke1 cells with low doses (starting dose 0.1 µM
424), selecting for cells that grew out, and increasing the concentration of 424
up to 1 µM. Cells were then treated with 5 µM simvastatin (sim) for 8 days and
counted using trypan blue. 5 µM sim prevented the outgrowth of Uke-P cells
growing in the presence of 1 µM 424. Experimental data represents a single
experiment which was replicated three times, with replicates supporting
presented data.

additional therapeutic strategies for MPN patients. Indeed, we now provide
evidence of the cooperation between statins and JAK inhibitors.
Our studies showing that multiple statins cooperate with multiple JAK
inhibitors in multiple JAK2-V617F-dependent cell lines are novel. We
demonstrate that statins cooperate with JAK inhibitors to enhance the reduction
in total viable cell numbers and viability compared to the single agents alone
(Figures 1-6). These data are relevant and intriguing for the current MPN field.
First, the results from the two phase 3 clinical trials involving INCB018424
(ruxolitinib), COMFORT-1 and COMFORT-2, did show that some patients did
better than others and it is still poorly understood why that is the case. A key
finding from the clinical trials with JAK2 inhibitors is that these inhibitors do not
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decrease allele burden [94, 205]. That is, they do not get rid of the neoplastic
MPN cells in patients. Therefore, an approach that enhances the efficacy of
MPN cell death in response to therapy is still needed in order to induce remission
in MPN patients. Second, it has been proposed that combination therapies of
JAK2 inhibitors and other agents may play a major role in future MPN therapies
[116-117]. For example, studies have shown cooperation between JAK2
inhibition and Hsp90 inhibitors as well as HDAC inhibitors on MPN cells. We
believe our studies suggest that statins may be another option for combinatorial
therapeutics with JAK2 inhibitors.
Importantly, we showed in two separate cases, with two separate JAK
inhibitors that statins are still effective at inducing cytotoxic effects in our JAK2V617F-driven cells that show signs of resistance. First, we show that after eight
days of treatment, HEL cells become resistant to the pan JAK inhibitor, JAK
Inhibitor I, Simvastatin treatment blocked the ability of the HEL cells treated with
JAK Inhibitor I to acquire resistance (Figure 24A). Second, we showed that low
dose simvastatin (5 µM) was effective at inhibiting the growth of Uke1-persistent
cells. These cells persistently grow in the presence of INCB018424, suggesting
that resistance or persistence to the JAK inhibitor does not also provide
resistance to the cytotoxic effects of simvastatin (Figure 33). Since some MPN
patients are resistant to the current standard of care (ex. Hydroxyurea) [29, 93,
95], we question if statins can provide therapeutic benefit in these cases. We
propose statins may provide benefit in MF or other MPN patients resistant or
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persistent to therapy, contributing to the management of the high peripheral cell
burden.
Further investigations are underway to determine the effect of combining
statin and JAK inhibitor on MPN cells. In collaboration with Ross Levine
(Memorial Sloan Kettering Cancer Center) we are utilizing an MPN mouse model
to determine if statins alone or in combination with JAK2 inhibition can inhibit
MPN formation in vivo. We will also be performing colony formation assays with
primary mononuclear cells from JAK2-V617F-positive MPN patients treated with
statins combined with 424.
Our assessment of the type of cooperation exhibited between statins and
INCB018424 demonstrated an additive cooperation. We did identify potential
dose combinations of statins (1.25 µM simvastatin combined with 0.15 µM
INCB018424) that may be synergistic, and we are currently investigating this
prospect further. It is important to consider that the Bliss cooperation analyses,
are short-term experiments, 72-96 hours, whereas the growth curve experiments
run between 192-264 hours and is where we can observe a significant effect of
statins. It will be interesting to determine if differences in the length of time of
experiments affects synergy designation.
Our studies described in this chapter are the first to demonstrate the
cooperation between JAK inhibitors and statins in JAK2-V617F-dependent cells.
We show that multiple statins cooperate with multiple JAK inhibitors in multiple
JAK2-V617F-dependent cells. We propose that statins combined with JAK
inhibitor therapy in patients may lead to an improved response compared to JAK
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inhibitor therapy alone. Statins may provide an affordable, safe therapeutic
addition to JAK-targeted therapy for MPN patients.

Materials and Methods
Growth curves
HEL, SET-2, Uke-1, or Uke1-P cells were plated at a concentration of 0.1 0.25 X 106 cells/mL and treated with 0 (dimethyl sulfoxide (DMSO)), 1 or 5 µM
simvastatin

(Sigma-Aldrich

#S6196),

lovastatin

(Sigma-Aldrich

#M2147),

atorvastatin (Sigma-Aldrich #PZ0001), 1 µM JAK Inhibitor I (Calbiochem
#420097), or 0.25 - 0.5 µM INCB018424 (Chemietek) alone, or in combination,
maintaining the DMSO content to 0.1% across all samples. Treated cells were
counted every two days with trypan blue using a hemocytometer. Cells were split
every two days, refreshing drugs and media.

Annexin V staining
HEL cells were treated with 0 (DMSO), 1 or 5 µM simvastatin or
atorvastatin, alone, or in combination with 0.25 - 0.5 µM INCB018424
(Chemietek) for 24 or 48 hours. 1 X 106 cells were washed with 1X PBS (room
temperature (RT)) and reconstituted in 100 µL of 5% BSA. 0.5 X 106 cells (50 µL)
were added to 50 µL 2X binding buffer (BD Biosciences), 8 µL [10 µg/mL]
propidium iodide (P.I.) (BD Biosciences), and 3 µL Annexin V-FITC (BD
Biosciences #556570), and incubated for 15 minutes at RT in the dark. 300 µL of
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1X binding buffer (BD Biosciences) were added and stained cells were analyzed
by flow cytometry (Calibur 2).

Cell cycle analysis
1 X 106 HEL cells were treated with 0 (DMSO), 1 or 5 µM simvastatin or
atorvastatin, alone, or in combination with 0.25 – 0.5 µM INCB018424
(Chemietek) for 24 or 48 hours. Cells were washed with 1X, RT PBS and
resuspended in 1X PBS. 900 µL of ice-cold 70% ethanol was added to 100 µL of
cells in PBS in a drop-wise fashion and vortexed on low speed. Cells were
incubated overnight at -20º C. After overnight incubation, samples were thawed
on ice and subsequently centrifuged at 14.5 X 105 X g for 60 seconds. Cells were
washed with 1X cold PBS and resuspended in 500 µL of (0.1% Triton-X-100-PBS
+ 10 µg/mL P.I. + 1 mg RNase A). Incubated sample in the dark for 30 minutes at
RT and analyzed by flow cytometry.

Bliss cooperation
HEL cells were treated with 0 (DMSO) to 20 µM simvastatin (Sigma
Aldrich #S6196) or 0 (DMSO) to 10 µM INCB018424 (Chemietek), alone or in
combination, in 384 well dishes at a plating confluency of 0.1 X 105 cells/mL.
Treatment incubations included 24, 48, and 72 hours at 37º C and 5% CO2.
DMSO content was maintained at 0.4% across all samples. Cell viability was
determined using Promega CellTiter Glo luminescence (Promega #G7571).
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Synergy was determined using % viability inhibition values and calculated using
the Bliss addivitity model [248].
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Chapter 5
Summary, Final Discussion, and Future Work

Summary and Discussion
Our work has provided multiple novel discoveries for the MPN field. First,
JAK2-V617F, a key etiologic factor for MPN development, is localized to lipid
rafts (Chapter 2). Second, JAK2-V617F signaling is dependent on lipid rafts
(Chapter 2). Third, MPN cells dependent on JAK2-V617F are sensitive to statin
treatment (Chapters 2 and 4). Fourth, statins cooperate with JAK2 inhibitors to
inhibit the growth and induce apoptosis of JAK2-V617F dependent cells (Chapter
4).
We have demonstrated that the localization of the JAK2-V617F mutant to
cholesterol-rich lipid rafts may be important for the full transforming potential of
this oncogene. Disruption of lipid rafts with agents that alter membrane
cholesterol reduced the localization of JAK2-V617F protein in lipid rafts (Figure 8
and 9). We found that multiple cholesterol alteration agents are effective at
downregulating JAK2/STAT signaling induced by JAK2-V617F (Figures 10A and
10C, respectively).
Currently, there are no lipid raft disrupting agents on the market for use in
humans, so to investigate functional aspects of targeting lipid rafts in JAK2V617F-driven MPN cells, we utilized the statin class of drugs. The JAK2/STAT
108

pathway is accepted as being crucial to MPNs and is therefore an appreciated
target for therapeutic intervention [65]. We hypothesized that cholesterol-lowering
statins may disrupt lipid rafts and hence, disrupt the JAK2-V617F signaling
complex at the membrane, ultimately attenuating JAK2/STAT signaling. Indeed,
cholesterol lowering statins downregulated JAK2/STAT signaling, inhibited cell
growth, and induced apoptosis in JAK2-V617F-dependent cells (Figure 10,
11A/B, and 12A/B, respectively). Very importantly, the cytotoxic effect of statins
was not only seen in MPN model cell lines, but primary JAK2-V617F-positive
MPN cells were also sensitive to low dose statin treatment.
Additionally, since JAK2 inhibitors alone are ineffective at reducing the
allele burden in MPN patients and thus fail to induce remission, the cooperativity
between statins and JAK2 inhibitors we have observed is highly relevant to a
need in the MPN field, that is, enhanced therapeutic killing of MPN cells.
Combination treatment with statins may provide opportunities to sensitize MPN
cells to JAK2-targeted therapy. This additional treatment, whether it is directed at
JAK2 signaling or not, may also decrease the development of de novo or innate
resistance that has been seen in MPN patients. Such a combination treatment
may also decrease the rate at which MPN patients transform to AML.
An important aspect to our work involves the dosage used in our
experiments. Our in vitro experiments are within physiological range that could
be tolerated in humans. Studies surrounding lovastatin showed that patients can
tolerate ~3.9 µM without any toxicities long-term [250]. It has also been shown
that patients given higher concentrations, ~12 µM for short time points (7 days) in
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cycles show no toxicity complications [250]. Another strategy has been employed
to avoid toxicity in patients given high doses of statins, whereby the cholesterol
precursor, squalene is supplemented, allowing patients to tolerate higher statin
doses [251]. Further investigation is needed to determine any implications of
therapeutic benefit with chronic concentrations such as these in MPNs.
In summary, we hypothesize that statins promote a cytotoxic effect in
MPN cells, and propose that statins, as a mono-therapy or more provocatively in
a combinatorial approach with JAK2 inhibitors, may provide an effective
therapeutic approach to improve the lives of MPN patients (Figure 34).

Proposed Model
statins

cholesterol or

protein
prenylation

?

downregulation of JAK/STAT signaling
opportunity to sensitize
cells to JAK2 inhibitor
therapy?
MPN cell cytotoxicity
Figure 34: Proposed model for targeting the mevalonate pathway with
statins in conjunction with JAK2 inhibitors in MPNs.

110

Future Work
We believe the work presented in this dissertation encourages additional
studies focused on investigating the potential role of lipid rafts in JAK2 signaling
in MPNs and the use of statins in novel therapeutic strategies for MPNs. We
intend to further investigate the role of lipid rafts in signaling driven by mutations
other than JAK2-V617F. Mutations of particular interest include JAK2 exon 12,
MPL, and LNK mutations. In addition, we would like to address the role of
cytokine receptors to further understand the sensitivity of JAK2-V617F signaling
to lipid raft alteration. For example, we are interested in comparing the sensitivity
to lipid raft disruption in the setting of EpoR/JAK2-V167F (important in PV)
versus MPL/JAK2-V617F (important in ET) versus GCSF-R/JAK2-V617F
(important in MF). This is of particular interest because the JAK2-V617F mutant
requires the expression of a cytokine receptor and these receptors may play
important roles in MPNs. We will also analyze the effects of statins alone, and in
combination with JAK2 inhibitors in JAK2-V617F-driven MPN murine models. In
addition, we will expand our studies with primary patient samples to determine
the extent to which statins cooperate with JAK2 inhibition in both JAK2-V617Fpositive and negative patient cells. With encouraging results from these and
other experiments, a clinical trial addressing statins in MPN therapy will be a
possibility in the near future.
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